BRISTOL MYERS SQUIBB CO, 10-Q filed on 4/29/2022
Quarterly Report
v3.22.1
Document and Entity Information
3 Months Ended
Mar. 31, 2022
shares
Document Type 10-Q
Document Quarterly Report true
Document Period End Date Mar. 31, 2022
Document Transition Report false
Entity File Number 001-01136
Entity Registrant Name BRISTOL-MYERS SQUIBB COMPANY
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 22-0790350
Entity Address, Address Line One 430 E. 29th Street, 14FL
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10016
City Area Code 212
Local Phone Number 546-4200
Entity Current Reporting Status Yes
Entity Interactive Data Current Yes
Entity Filer Category Large Accelerated Filer
Entity Emerging Growth Company false
Entity Shell Company false
Entity Common Stock, Shares Outstanding 2,129,064,271
Entity Central Index Key 0000014272
Document Fiscal Year Focus 2022
Document Fiscal Period Focus Q1
Current Fiscal Year End Date --12-31
Amendment Flag false
Entity Small Business false
Common Stock $0.10 Par Value  
Title of 12(b) Security Common Stock, $0.10 Par Value
Trading Symbol BMY
Security Exchange Name NYSE
1.000% Notes due 2025  
Title of 12(b) Security 1.000% Notes due 2025
Trading Symbol BMY25
Security Exchange Name NYSE
1.750% Notes due 2035  
Title of 12(b) Security 1.750% Notes due 2035
Trading Symbol BMY35
Security Exchange Name NYSE
Celgene Contingent Value Rights  
Title of 12(b) Security Celgene Contingent Value Rights
Trading Symbol CELG RT
Security Exchange Name NYSE
v3.22.1
CONSOLIDATED STATEMENTS OF EARNINGS (UNAUDITED) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Total Revenues $ 11,648 $ 11,073
Cost of products sold [1] 2,471 2,841
Marketing, selling and administrative 1,831 1,666
Research and development 2,260 2,219
Acquired IPRD 333 6
Amortization of acquired intangible assets 2,417 2,513
Other (income)/expense, net 649 (702)
Total Expenses 9,961 8,543
Earnings Before Income Taxes 1,687 2,530
Provision for Income Taxes 404 501
Net Earnings 1,283 2,029
Noncontrolling Interest 5 8
Net Earnings Attributable to BMS $ 1,278 $ 2,021
Earnings per common share attributable to BMS, basic (in usd per share) $ 0.60 $ 0.90
Earnings per common share attributable to BMS, diluted (in usd per share) $ 0.59 $ 0.89
Net product sales    
Total Revenues $ 11,308 $ 10,798
Alliance and other revenues    
Total Revenues $ 340 $ 275
[1] Excludes amortization of acquired intangible assets
v3.22.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Statement of Comprehensive Income [Abstract]    
Net Earnings $ 1,283 $ 2,029
Derivatives qualifying as cash flow hedges 31 280
Pension and postretirement benefits 21 23
Marketable debt securities (1) (2)
Foreign currency translation (12) (6)
Total Other Comprehensive Income 39 295
Comprehensive Income 1,322 2,324
Comprehensive Income Attributable to Noncontrolling Interest 5 8
Comprehensive Income Attributable to BMS $ 1,317 $ 2,316
v3.22.1
CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Current Assets:    
Cash and cash equivalents $ 12,369 $ 13,979
Marketable debt securities 2,599 2,987
Receivables 8,511 9,369
Inventories 2,104 2,095
Other current assets 4,538 4,832
Total Current Assets 30,121 33,262
Property, plant and equipment 6,047 6,049
Goodwill 20,500 20,502
Other intangible assets 40,103 42,527
Deferred income taxes 1,418 1,439
Other non-current assets 4,845 5,535
Total Assets 103,034 109,314
Current Liabilities:    
Short-term debt obligations 7,522 4,948
Accounts payable 2,944 2,949
Other current liabilities 12,355 13,971
Total Current Liabilities 22,821 21,868
Deferred income taxes 3,809 4,501
Long-term debt 37,450 39,605
Other non-current liabilities 7,309 7,334
Total Liabilities 71,389 73,308
Bristol-Myers Squibb Company Shareholders’ Equity:    
Preferred stock 0 0
Common stock 292 292
Capital in excess of par value of stock 43,756 44,361
Accumulated other comprehensive loss (1,229) (1,268)
Retained earnings 23,948 23,820
Less cost of treasury stock (35,187) (31,259)
Total Bristol-Myers Squibb Company Shareholders’ Equity 31,580 35,946
Noncontrolling interest 65 60
Total Equity 31,645 36,006
Total Liabilities and Equity $ 103,034 $ 109,314
v3.22.1
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash Flows From Operating Activities:    
Net Earnings $ 1,283 $ 2,029
Adjustments to reconcile net earnings to net cash provided by operating activities:    
Depreciation and amortization, net 2,584 2,668
Deferred income taxes (687) 68
Stock-based compensation 107 151
Impairment charges 41 339
Pension settlements and amortization 7 11
Divestiture gains and royalties (387) (135)
Acquired IPRD 333 6
Equity investment losses/(gains) 644 (601)
Contingent consideration fair value adjustments 1 (510)
Other adjustments 248 233
Changes in operating assets and liabilities:    
Receivables 786 67
Inventories 1 106
Accounts payable 23 303
Rebates and discounts (930) (221)
Income taxes payable 831 227
Other (1,073) (917)
Net Cash Provided by Operating Activities 3,812 3,824
Cash Flows From Investing Activities:    
Sale and maturities of marketable debt securities 2,100 782
Purchase of marketable debt securities (1,714) (1,302)
Proceeds from sales of equity investment securities 2 405
Capital expenditures (253) (173)
Divestiture and other proceeds 402 180
Acquisition and other payments, net of cash acquired (442) (35)
Net Cash Provided by/(Used in) Investing Activities 95 (143)
Cash Flows From Financing Activities:    
Short-term debt obligations, net 42 (62)
Issuance of long-term debt 5,926 0
Repayment of long-term debt (5,769) (4,522)
Repurchase of common stock (5,000) (1,775)
Dividends (1,185) (1,108)
Other 333 172
Net Cash Used in Financing Activities (5,653) (7,295)
Effect of Exchange Rates on Cash, Cash Equivalents and Restricted Cash 9 (38)
Decrease in Cash, Cash Equivalents and Restricted Cash (1,737) (3,652)
Cash, Cash Equivalents and Restricted Cash at Beginning of Period 14,316 14,973
Cash, Cash Equivalents and Restricted Cash at End of Period $ 12,579 $ 11,321
v3.22.1
BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING STANDARDS (Notes)
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Basis of Presentation and Recently Issued Accounting Standards BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING STANDARDS
Basis of Consolidation

Bristol-Myers Squibb Company (“BMS” or “the Company”) prepared these unaudited consolidated financial statements following the requirements of the SEC and U.S. GAAP for interim reporting. Under those rules, certain footnotes and other financial information that are normally required for annual financial statements can be condensed or omitted. The Company is responsible for the consolidated financial statements included in this Quarterly Report on Form 10-Q, which include all adjustments necessary for a fair presentation of the financial position at March 31, 2022 and December 31, 2021 and the results of operations and cash flows for the three months ended March 31, 2022 and 2021. All intercompany balances and transactions have been eliminated. These financial statements and the related notes should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2021 included in the 2021 Form 10-K. Refer to the Summary of Abbreviated Terms at the end of this Quarterly Report on Form 10-Q for terms used throughout the document.

Business Segment Information

BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the discovery, development, manufacturing and supply of products. Regional commercial organizations market, distribute and sell the products. The business is also supported by global corporate staff functions. Consistent with BMS’s operational structure, the Chief Executive Officer (“CEO”), as the chief operating decision maker, manages and allocates resources at the global corporate level. Managing and allocating resources at the global corporate level enables the CEO to assess both the overall level of resources available and how to best deploy these resources across functions, therapeutic areas, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or franchise basis. The determination of a single segment is consistent with the financial information regularly reviewed by the CEO for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods. For further information on product and regional revenue, see “—Note 2. Revenue”.

Use of Estimates and Judgments

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Accordingly, the results and trends in these unaudited consolidated financial statements may not be indicative of full year operating results. The preparation of financial statements requires the use of management estimates, judgments and assumptions. The most significant assumptions are estimates used in determining accounting for acquisitions; impairments of goodwill and intangible assets; chargebacks, cash discounts, sales rebates, returns and other adjustments; legal contingencies; and income taxes. Actual results may differ from estimates.

Reclassifications

Certain reclassifications were made to conform the prior period consolidated financial statements to the current period presentation. Up-front and contingent milestone charges in connection with asset acquisitions or licensing of third-party intellectual property rights previously presented in Research and development are now presented in Acquired IPRD in the consolidated statement of earnings. Proceeds received from the sale of equity investment securities previously presented in Divestiture and other proceeds in the consolidated statements of cash flows is now presented separately in Proceeds from sales of equity investment securities. Additionally, Rebates and discounts previously presented in Other changes in operating assets and liabilities in the consolidated statements of cash flows is now presented separately in Rebates and discounts.

Recently Issued Accounting Standards Not Yet Adopted

Business Combinations

In October 2021, the FASB issued amended guidance on accounting for contract assets and contract liabilities from contracts with customers in a business combination. The guidance is intended to address inconsistency related to recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized. At the acquisition date, an entity should account for the related revenue contracts in accordance with existing revenue recognition guidance generally by assessing how the acquiree applied recognition and measurement in their financial statements. The amended guidance is effective January 1, 2023 on a prospective approach. Early adoption is permitted.
v3.22.1
Revenue
3 Months Ended
Mar. 31, 2022
Revenue from Contract with Customer [Abstract]  
Revenue REVENUE
The following table summarizes the disaggregation of revenue by nature:
Three Months Ended March 31,
Dollars in Millions20222021
Net product sales$11,308 $10,798 
Alliance revenues188 142 
Other revenues152 133 
Total Revenues$11,648 $11,073 

The following table summarizes GTN adjustments:
Three Months Ended March 31,
Dollars in Millions20222021
Gross product sales$16,650 $15,559 
GTN adjustments(a)
Charge-backs and cash discounts(1,763)(1,586)
Medicaid and Medicare rebates(2,084)(1,718)
Other rebates, returns, discounts and adjustments(1,495)(1,457)
Total GTN adjustments(5,342)(4,761)
Net product sales$11,308 $10,798 
(a)    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $74 million and $217 million for the three months ended March 31, 2022, and 2021, respectively.

The following table summarizes the disaggregation of revenue by product and region:
Three Months Ended March 31,
Dollars in Millions20222021
In-Line Products
Eliquis$3,211 $2,886 
Opdivo1,923 1,720 
Pomalyst/Imnovid826 773 
Orencia792 758 
Sprycel483 470 
Yervoy515 456 
Empliciti75 85 
Mature and other products462 506 
New Product Portfolio
Reblozyl156 112 
Abecma67 — 
Zeposia36 18 
Breyanzi44 — 
Inrebic18 16 
Onureg23 15 
Opdualag— 
Recent LOE Products(a)
Revlimid2,797 2,944 
Abraxane214 314 
Total Revenues$11,648 $11,073 
United States$7,694 $7,010 
Europe2,413 2,553 
Rest of the World1,314 1,346 
Other(b)
227 164 
Total Revenues$11,648 $11,073 
(a)    Recent LOE Products includes products with significant decline in revenue from the prior reporting period as a result of a loss of exclusivity.
(b)    Other revenues include royalties and alliance-related revenues for products not sold by BMS’s regional commercial organizations.
Revenue recognized from performance obligations satisfied in prior periods was $147 million and $284 million for the three months ended March 31, 2022 and 2021, respectively, consisting primarily of revised estimates for GTN adjustments related to prior period sales and royalties for out-licensing arrangements.
v3.22.1
ALLIANCES
3 Months Ended
Mar. 31, 2022
ALLIANCES [Abstract]  
Alliances ALLIANCES
BMS enters into collaboration arrangements with third parties for the development and commercialization of certain products. Although each of these arrangements is unique in nature, both parties are active participants in the operating activities of the collaboration and exposed to significant risks and rewards depending on the commercial success of the activities. BMS may either in-license intellectual property owned by the other party or out-license its intellectual property to the other party. These arrangements also typically include research, development, manufacturing, and/or commercial activities and can cover a single investigational compound or commercial product or multiple compounds and/or products in various life cycle stages. The rights and obligations of the parties can be global or limited to geographic regions. BMS refers to these collaborations as alliances and its partners as alliance partners.

Selected financial information pertaining to alliances was as follows, including net product sales when BMS is the principal in the third-party customer sale for products subject to the alliance. Expenses summarized below do not include all amounts attributed to the activities for the products in the alliance, but only the payments between the alliance partners or the related amortization if the payments were deferred or capitalized.
Three Months Ended March 31,
Dollars in Millions20222021
Revenues from alliances:
Net product sales$3,239 $2,882 
Alliance revenues188 142 
Total Revenues$3,427 $3,024 
Payments to/(from) alliance partners:
Cost of products sold$1,556 $1,397 
Marketing, selling and administrative(54)(49)
Research and development22 
Other (income)/expense, net(12)(5)
Dollars in MillionsMarch 31,
2022
December 31,
2021
Selected Alliance Balance Sheet information:
Receivables – from alliance partners$304 $320 
Accounts payable – to alliance partners1,504 1,229 
Deferred income from alliances(a)
326 330 
(a)    Includes unamortized upfront and milestone payments.

The nature, purpose, significant rights and obligations of the parties and specific accounting policy elections for each of the Company's significant alliances are discussed in the 2021 Form 10-K. Significant developments and updates related to alliances during the three months ended March 31, 2022 are set forth below.

Nektar

In April 2022, BMS and Nektar announced that the companies have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo based on results from pre-planned analyses of two late-stage clinical studies in RCC and bladder cancer. These studies and all other ongoing studies in the program will be discontinued.
v3.22.1
DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS (Notes)
3 Months Ended
Mar. 31, 2022
Acquisitions, Divestitures and Other Arrangements [Abstract]  
Divestitures, Licensing and Other Arrangements DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS
Divestitures

The following table summarizes the financial impact of divestitures including royalties, which are included in Other (income)/expense, net. Revenue and pretax earnings related to all divestitures were not material in all periods presented (excluding divestiture gains or losses).
Three Months Ended March 31,
Net Proceeds(a)
Divestiture (Gains)/LossesRoyalty Income
Dollars in Millions202220212022202120222021
Diabetes Business$172 $164 $— $— $(170)$(134)
Mature Products and Other225 16 (211)— (1)(1)
Total$397 $180 $(211)$— $(171)$(135)
(a)    Includes royalties received subsequent to the related sale of the asset or business.

Mature Products and Other

In the three months ended March 31, 2022, product rights to several mature products were sold to Cheplapharm resulting in cash proceeds of $221 million and divestiture gain of $211 million.

Licensing and Other Arrangements

The following table summarizes the financial impact of Keytruda* royalties, Tecentriq* royalties, up-front licensing fees and milestones for products that have not obtained commercial approval, which are included in Other (income)/expense, net.
Three Months Ended March 31,
Dollars in Millions20222021
Keytruda* royalties
$(221)$(192)
Tecentriq* royalties
(25)(22)
Contingent milestone income(41)— 
Amortization of deferred income(12)(15)
Other royalties(7)(3)
Total$(306)$(232)

In-license Arrangements

Immatics

In the three months ended March 31, 2022, BMS obtained a global exclusive license to Immatics’ TCR bispecific IMA401 program. IMA401 is being studied in oncology and a Clinical Trial Application has been approved by the German federal regulatory authority and the trial is planned to commence in the first half of 2022. BMS and Immatics will collaborate on the development and BMS will be responsible for the commercialization of IMA401 and its related products worldwide, including strategic decisions, regulatory responsibilities, funding and manufacturing. Immatics has the option to co-fund U.S. development in exchange for enhanced U.S. royalty payments and/or to co-promote IMA401 in the U.S. The transaction included an up-front payment of $150 million which was included in Acquired IPRD and Immatics is eligible to receive contingent development, regulatory and sales-based milestones of up to $770 million as well as royalties on global net sales.

Dragonfly

In the three months ended March 31, 2022, a Phase I development milestone for interlukin-12 (“IL-12”) was achieved resulting in a $175 million payment to Dragonfly and an Acquired IPRD charge. The parties also amended the terms of three future milestones by requiring the achievement of certain criteria by specified dates unless BMS notifies Dragonfly that it will discontinue development of IL-12. These milestones continue to be considered substantive and contingent because the decision to proceed will be based on an assessment of clinical data prior to the specified dates.
Other

MyoKardia

In April 2022, BMS amended the terms of a license arrangement and paid a third party $295 million to extinguish a future royalty obligation related to mavacamten prior to its FDA approval which will result in an Acquired IPRD charge.
v3.22.1
OTHER (INCOME)/EXPENSE, NET
3 Months Ended
Mar. 31, 2022
Other Nonoperating Income (Expense) [Abstract]  
Other (Income)/Expense, Net OTHER (INCOME)/EXPENSE, NET
Three Months Ended March 31,
Dollars in Millions20222021
Interest expense$326 $353 
Royalties and licensing income(477)(367)
Equity investment losses/(gains)644 (601)
Integration expenses105 141 
Contingent consideration(510)
Loss on debt redemption275 281 
Provision for restructuring23 45 
Litigation and other settlements(37)(8)
Transition and other service fees(1)(15)
Investment income(10)(9)
Divestiture gains(211)— 
Other11 (12)
Other (income)/expense, net$649 $(702)
v3.22.1
RESTRUCTURING
3 Months Ended
Mar. 31, 2022
Restructuring Charges [Abstract]  
Restructuring RESTRUCTURING
Celgene Acquisition Plan

In 2019, a restructuring and integration plan was implemented as an initiative to realize sustainable run rate synergies resulting from cost savings and avoidance from the Celgene acquisition that are currently expected to be approximately $3.0 billion. The synergies are expected to be realized in Cost of products sold (5%), Marketing, selling and administrative expenses (65%) and Research and development expenses (30%). Charges of approximately $3.3 billion are expected to be incurred. The majority of the charges are expected to be incurred through 2022. Cumulative charges of approximately $2.7 billion have been recognized to date including integration planning and execution expenses, employee termination benefit costs and accelerated stock-based compensation, contract termination costs and other shutdown costs associated with site exits. Cash outlays in connection with these actions are expected to be approximately $3.0 billion. Employee workforce reductions were approximately 60 for the three months ended March 31, 2022 and 2021.

MyoKardia Acquisition Plan

In 2020, a restructuring and integration plan was initiated to realize expected cost synergies resulting from cost savings and avoidance from the MyoKardia acquisition. Charges of approximately $150 million are expected to be incurred through 2022, and consist of integration planning and execution expenses, employee termination benefit costs and other costs. Cumulative charges of approximately $120 million have been recognized for these actions to date.
The following provides the charges related to restructuring initiatives by type of cost:
Three Months Ended March 31,
Dollars in Millions20222021
Celgene Acquisition Plan$127 $173 
MyoKardia Acquisition Plan37 
Total charges$130 $210 
Employee termination costs$22 $44 
Other termination costs
Provision for restructuring23 45 
Integration expenses105 141 
Accelerated depreciation— 
Asset impairments— 24 
Total charges$130 $210 
Cost of products sold$— $24 
Marketing, selling and administrative— 
Other (income)/expense, net128 186 
Total charges$130 $210 

The following summarizes the charges and spending related to restructuring plan activities:
Three Months Ended March 31,
Dollars in Millions20222021
Liability at December 31$101 $148 
Provision for restructuring(a)
23 39 
Foreign currency translation and other(1)(2)
Payments(21)(59)
Liability at March 31
$102 $126 
(a)    Includes a reduction of the liability resulting from changes in estimates of $9 million and $1 million for the three months ended March 31, 2022 and 2021, respectively. Excludes $6 million for the three months ended March 31, 2021 of accelerated stock-based compensation relating to the Celgene Acquisition Plan.
v3.22.1
INCOME TAXES
3 Months Ended
Mar. 31, 2022
Income Tax Disclosure [Abstract]  
Income Taxes INCOME TAXES
Three Months Ended March 31,
Dollars in Millions20222021
Earnings Before Income Taxes$1,687 $2,530 
Provision for Income Taxes404 501 
Effective Tax Rate23.9 %19.8 %

Income taxes in interim periods are determined based on the estimated annual effective tax rates and the tax impact of discrete items that are reflected immediately. The effective tax rates in 2022 and 2021 were impacted by low jurisdictional tax rates attributed to the unwinding of inventory fair value adjustments and intangible asset amortization and contingent value rights fair value adjustments that were not taxable in 2021. Additional changes to the effective tax rate may occur in future periods due to various reasons, including changes to the estimated pretax earnings mix and tax reserves and revised interpretations or changes to the relevant tax code.

It is reasonably possible that the amount of unrecognized tax benefits at March 31, 2022 could decrease in the range of approximately $450 million to $500 million in the next twelve months as a result of the settlement of certain tax audits and other events. The expected change in unrecognized tax benefits may result in the payment of additional taxes, adjustment of certain deferred taxes and/or recognition of tax benefits.

BMS is currently under examination by a number of tax authorities, which have proposed or are considering proposing material adjustments to tax positions for issues such as transfer pricing, certain tax credits and the deductibility of certain expenses. As previously disclosed, BMS received several notices of proposed adjustments from the IRS related to transfer pricing and other tax positions for the 2008 to 2012 tax years. BMS disagrees with the IRS’s positions and continues to work cooperatively with the IRS to resolve these open tax audits. It is reasonably possible that new issues will be raised by tax authorities that may increase unrecognized tax benefits; however, an estimate of such increases cannot reasonably be made at this time. BMS believes that it has adequately provided for all open tax years by tax jurisdiction.
v3.22.1
EARNINGS PER SHARE
3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
Earnings Per Share EARNINGS PER SHARE
Three Months Ended March 31,
Amounts in Millions, Except Per Share Data20222021
Net Earnings Attributable to BMS Used for Basic and Diluted EPS Calculation$1,278 $2,021 
Weighted-Average Common Shares Outstanding – Basic2,146 2,236 
Incremental Shares Attributable to Share-Based Compensation Plans18 29 
Weighted-Average Common Shares Outstanding – Diluted2,164 2,265 
Earnings per Common Share
Basic$0.60 $0.90 
Diluted0.59 0.89 

The total number of potential shares of common stock excluded from the diluted earnings per common share computation because of the antidilutive impact was not material for the three months ended March 31, 2022 and 2021.
v3.22.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
3 Months Ended
Mar. 31, 2022
Fair Value Disclosures [Abstract]  
Financial Instruments and Fair Value Measurements FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
March 31, 2022December 31, 2021
Dollars in MillionsLevel 1Level 2Level 3Level 1Level 2Level 3
Cash and cash equivalents - money market and other securities$— $9,467 $— $— $12,225 $— 
Marketable debt securities:
Certificates of deposit— 2,013 — — 2,264 — 
Commercial paper— 325 — — 320 — 
Corporate debt securities— 261 — — 403 — 
Derivative assets— 288 10 — 206 12 
Equity investments1,410 44 — 1,910 109 — 
Derivative liabilities— 58 — — 25 — 
Contingent consideration liability:
Contingent value rights— — — — 
Other acquisition related contingent consideration— — 34 — — 35 

As further described in “Item 8. Financial Statements and Supplementary Data—Note 9. Financial Instruments and Fair Value Measurements” in the Company’s 2021 Form 10-K, the Company’s fair value estimates use inputs that are either (1) quoted prices for identical assets or liabilities in active markets (Level 1 inputs); (2) observable prices for similar assets or liabilities in active markets or for identical or similar assets or liabilities in markets that are not active (Level 2 inputs); or (3) unobservable inputs (Level 3 inputs).
Contingent consideration obligations are recorded at their estimated fair values and these obligations are revalued each reporting period until the related contingencies are resolved. The contingent value rights are adjusted to fair value using the traded price of the securities at the end of each reporting period. The fair value measurements for other contingent consideration liabilities are estimated using probability-weighted discounted cash flow approaches that are based on significant unobservable inputs related to product candidates acquired in business combinations and are reviewed quarterly. These inputs include, as applicable, estimated probabilities and timing of achieving specified development and regulatory milestones and the discount rate used to calculate the present value of estimated future payments. Significant changes which increase or decrease the probabilities of achieving the related development and regulatory events or shorten or lengthen the time required to achieve such events would result in corresponding increases or decreases in the fair values of these obligations.

Marketable Debt Securities and Equity Investments

The following table summarizes marketable debt securities:
March 31, 2022December 31, 2021
Dollars in MillionsAmortized CostGross UnrealizedAmortized CostGross Unrealized
GainsLossesFair ValueGainsLossesFair Value
Certificates of deposit$2,013 $— $— $2,013 $2,264 $— $— $2,264 
Commercial paper325 — — 325 320 — — 320 
Corporate debt securities260 — 261 401 — 403 
Total marketable debt securities(a)
$2,598 $$— $2,599 $2,985 $$— $2,987 
(a)    All marketable debt securities mature within one year as of March 31, 2022 and December 31, 2021.

The following summarizes the carrying amount of equity investments:
Dollars in MillionsMarch 31,
2022
December 31,
2021
Equity investments with readily determinable fair values$1,454 $2,019 
Equity investments without readily determinable fair values330 283 
Equity method investments629 666 
Total equity investments$2,413 $2,968 

The following summarizes the activity related to equity investments. Changes in fair value of equity investments are included in Other (income)/expense, net.
Three Months Ended March 31,
Dollars in Millions20222021
Equity investments with readily determined fair values(a)
Net loss/(gain) recognized$598 $(196)
Net loss recognized on investments sold— 
Net unrealized loss/(gain) recognized on investments still held598 (199)
Equity investments without readily determinable fair values
Upward adjustments(6)(269)
Impairments and downward adjustments
Cumulative upward adjustments(109)
Cumulative impairments and downward adjustments52 
Equity in net (income)/loss of affiliates50 (137)
(a)    Certain prior year amounts have been reclassified to conform to the current year's presentation.

Qualifying Hedges and Non-Qualifying Derivatives

Cash Flow Hedges — Foreign currency forward contracts are used to hedge certain forecasted intercompany inventory purchases and sales transactions and certain foreign currency transactions. The fair value for contracts designated as cash flow hedges is temporarily reported in Accumulated other comprehensive loss and included in earnings when the hedged item affects earnings. The net gain or loss on foreign currency forward contracts is expected to be reclassified to net earnings (primarily included in Cost of products sold and Other (income)/expense, net) within the next 24 months. The notional amount of outstanding foreign currency forward contracts was primarily attributed to the euro of $5.3 billion and Japanese yen of $1.3 billion at March 31, 2022.
The earnings impact related to discontinued cash flow hedges and hedge ineffectiveness was not material during all periods presented. Cash flow hedge accounting is discontinued when the forecasted transaction is no longer probable of occurring within 60 days after the originally forecasted date or when the hedge is no longer effective. Assessments to determine whether derivatives designated as qualifying hedges are highly effective in offsetting changes in the cash flows of hedged items are performed at inception and on a quarterly basis. Foreign currency forward contracts not designated as hedging instruments are used to offset exposures in certain foreign currency denominated assets, liabilities and earnings. Changes in the fair value of these derivatives are recognized in earnings as they occur.

Net Investment Hedges — Non-U.S. dollar borrowings of €950 million ($1.1 billion) at March 31, 2022 are designated as net investment hedges to hedge euro currency exposures of the net investment in certain foreign affiliates and are recognized in long-term debt. The effective portion of foreign exchange gain on the remeasurement of euro debt was included in the foreign currency translation component of Accumulated other comprehensive loss with the related offset in long-term debt.

Cross-currency interest rate swap contracts of $600 million at March 31, 2022 are designated to hedge Japanese yen currency exposure of BMS’s net investment in its Japan subsidiaries. Contract fair value changes are recorded in the foreign currency translation component of Accumulated other comprehensive loss with a related offset in Other non-current assets or Other non-current liabilities.

Fair Value Hedges — Fixed to floating interest rate swap contracts are designated as fair value hedges and used as an interest rate risk management strategy to create an appropriate balance of fixed and floating rate debt. The contracts and underlying debt for the hedged benchmark risk are recorded at fair value. The effective interest rate for the contracts is one-month LIBOR (0.45% as of March 31, 2022) plus an interest rate spread of 4.6%. Gains or losses resulting from changes in fair value of the underlying debt attributable to the hedged benchmark interest rate risk are recorded in interest expense with an associated offset to the carrying value of debt. Since the specific terms and notional amount of the swap are intended to align with the debt being hedged, all changes in fair value of the swap are recorded in interest expense with an associated offset to the derivative asset or liability on the consolidated balance sheet. As a result, there was no net impact in earnings. If the underlying swap is terminated prior to maturity, then the fair value adjustment to the underlying debt is amortized as a reduction to interest expense over the remaining term of the debt.

In February 2022, Treasury lock contracts were entered into with a total notional value of $3.0 billion to hedge interest rate risk associated with the anticipated issuance of long-term debt. The Treasury lock contracts were terminated upon the issuance of the aggregate $6.0 billion of unsecured senior notes. These contracts were not designated for hedge accounting. The settlement of these contracts were not material.

In March 2022, Treasury lock contracts were entered into with a total notional value of $2.3 billion to hedge cash payment for the anticipated redemption of long-term debt. The Treasury lock contracts were terminated upon pricing the debt redemption. These contracts were not designated for hedge accounting. The settlement of these contracts were not material.

The following table summarizes the fair value of outstanding derivatives:
 March 31, 2022December 31, 2021
Asset(a)
Liability(b)
Asset(a)
Liability(b)
Dollars in MillionsNotionalFair ValueNotionalFair ValueNotionalFair ValueNotionalFair Value
Derivatives designated as hedging instruments:
Interest rate swap contracts$— $— $255 $(3)$255 $10 $— $— 
Cross-currency interest rate swap contracts450 37 150 (1)600 26 — — 
Foreign currency forward contracts5,409 230 2,492 (44)3,587 161 1,814 (20)
Derivatives not designated as hedging instruments:
Foreign currency forward contracts744 21 629 (10)883 568 (5)
Other— 10 — — — 12 — — 
(a)    Included in Other current assets and Other non-current assets.
(b)    Included in Other current liabilities and Other non-current liabilities.
The following table summarizes the financial statement classification and amount of (gain)/loss recognized on hedging instruments:
Three Months Ended March 31, 2022Three Months Ended March 31, 2021
Dollars in MillionsCost of products soldOther (income)/expense, netCost of products soldOther (income)/expense, net
Interest rate swap contracts$— $(11)$— $(8)
Cross-currency interest rate swap contracts— (4)— (3)
Foreign currency forward contracts(82)(57)67 (32)

The following table summarizes the effect of derivative and non-derivative instruments designated as hedging instruments in Other Comprehensive Income:
Three Months Ended March 31,
Dollars in Millions20222021
Derivatives qualifying as cash flow hedges
Foreign currency forward contracts gain/(loss):
Recognized in Other Comprehensive Income(a)
$120 $259 
Reclassified to Cost of products sold(82)36 
Forward starting interest rate swap contract loss:
Reclassified to Other (income)/expense, net(3)— 
Derivatives qualifying as net investment hedges
Cross-currency interest rate swap contracts gain:
Recognized in Other Comprehensive Income13 26 
Non-derivatives qualifying as net investment hedges
Non-U.S. dollar borrowings gain:
Recognized in Other Comprehensive Income15 41 
(a)    The majority is expected to be reclassified into earnings in the next 18 months.

Debt Obligations

Short-term debt obligations include:
Dollars in MillionsMarch 31,
2022
December 31,
2021
Non-U.S. short-term borrowings$130 $105 
Current portion of long-term debt7,297 4,764 
Other95 79 
Total$7,522 $4,948 
Long-term debt and the current portion of long-term debt include:
Dollars in MillionsMarch 31,
2022
December 31,
2021
Principal Value$43,925 $43,095 
Adjustments to Principal Value:
Fair value of interest rate swap contracts(4)10 
Unamortized basis adjustment from swap terminations113 119 
Unamortized bond discounts and issuance costs(303)(263)
Unamortized purchase price adjustments of Celgene debt1,016 1,408 
Total$44,747 $44,369 
Current portion of long-term debt$7,297 $4,764 
Long-term debt37,450 39,605 
Total$44,747 $44,369 

The fair value of long-term debt was $45.8 billion at March 31, 2022 and $49.1 billion at December 31, 2021 valued using Level 2 inputs, which are based upon the quoted market prices for the same or similar debt instruments. The fair value of short-term borrowings approximates the carrying value due to the short maturities of the debt instruments.

In the three months ended March 31, 2022, BMS issued an aggregate principal amount of $6.0 billion of debt consisting of $1.75 billion of 2.950% Notes due 2032, $1.25 billion of 3.550% Notes due 2042, $2.0 billion of 3.700% Notes due 2052 and $1.0 billion of 3.900% Notes due 2062 with proceeds net of discount and deferred loan issuance costs of $5.9 billion. The notes rank equally in right of payment with all of BMS's existing and future senior unsecured indebtedness and are redeemable at any time, in whole, or in part, at varying specified redemption prices plus accrued and unpaid interest.

Additionally, BMS purchased aggregate principal amount of $5.2 billion of certain of its debt securities for approximately $5.8 billion of cash in tender offers. In connection with these transactions, a $275 million loss on debt redemption was recognized based on the carrying value of the debt and included in Other (income)/expense, net.

In April 2022, BMS purchased aggregate principal amount of $849 million of certain of its debt securities for approximately $880 million of cash pursuant to “make whole” redemptions.

In the three months ended March 31, 2021, BMS purchased aggregate principal amount of $3.5 billion of certain of its debt securities for approximately $4.0 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $281 million loss on debt redemption was recognized based on the carrying value of the debt and included in Other (income)/expense, net. In addition, the $500 million 2.875% Notes matured and were repaid.

Interest payments were $377 million and $435 million for the three months ended March 31, 2022 and 2021, respectively, net of amounts related to interest rate swap contracts.

At December 31, 2021, we had four separate revolving credit facilities totaling $6.0 billion, which consisted of a 364-day $2.0 billion facility which expired in January 2022, a three-year $1.0 billion facility which expired in January 2022 and two five-year $1.5 billion facilities that were extended to September 2025 and July 2026, respectively.

In January 2022, we entered into a five-year $5.0 billion facility expiring in January 2027, which is extendable annually by one year with the consent of the lenders. This facility provides for customary terms and conditions with no financial covenants and may be used to provide backup liquidity for our commercial paper borrowings. Concurrently with the entry into this facility, the commitments under our existing five-year $1.5 billion facilities were terminated and the three-year $1.0 billion facility and 364-day $2.0 billion facility expired in accordance with their terms in January 2022. No borrowings were outstanding under any revolving credit facility at March 31, 2022 or December 31, 2021.
v3.22.1
RECEIVABLES
3 Months Ended
Mar. 31, 2022
Accounts Receivable, after Allowance for Credit Loss [Abstract]  
Receivables RECEIVABLES
Dollars in MillionsMarch 31,
2022
December 31,
2021
Trade receivables$7,746 $8,723 
Less charge-backs and cash discounts(561)(723)
Less allowance for expected credit loss(29)(21)
Net trade receivables7,156 7,979 
Alliance, Royalties, VAT and other1,355 1,390 
Receivables$8,511 $9,369 

Non-U.S. receivables sold on a nonrecourse basis were $423 million and $318 million for the three months ended March 31, 2022 and 2021, respectively. Receivables from the three largest customers in the U.S. represented approximately 60% and 59% of total trade receivables at March 31, 2022 and December 31, 2021, respectively.
v3.22.1
INVENTORIES
3 Months Ended
Mar. 31, 2022
Inventory, Net [Abstract]  
Inventories INVENTORIES
Dollars in MillionsMarch 31,
2022
December 31,
2021
Finished goods$449 $543 
Work in process2,052 2,111 
Raw and packaging materials446 350 
Total inventories$2,947 $3,004 
Inventories$2,104 $2,095 
Other non-current assets843 909 

Total inventories include fair value adjustments resulting from the Celgene acquisition of $368 million at March 31, 2022 and $508 million at December 31, 2021. Other non-current assets include inventory expected to remain on hand beyond 12 months in both periods.

An out of period adjustment was included in the three months ended March 31, 2022 to reduce the remaining amount of inventory fair value adjustments resulting from the Celgene acquisition by $114 million with a corresponding increase to Cost of products sold of $32 million and Research and development expense of $82 million. The adjustment was not material to previously reported balance sheets or results of operations.
v3.22.1
PROPERTY, PLANT AND EQUIPMENT
3 Months Ended
Mar. 31, 2022
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment PROPERTY, PLANT AND EQUIPMENT
Dollars in MillionsMarch 31,
2022
December 31,
2021
Land$168 $169 
Buildings5,941 5,897 
Machinery, equipment and fixtures3,306 3,252 
Construction in progress800 764 
Gross property, plant and equipment10,215 10,082 
Less accumulated depreciation(4,168)(4,033)
Property, plant and equipment$6,047 $6,049 

Depreciation expense was $145 million and $135 million for the three months ended March 31, 2022 and 2021, respectively.
v3.22.1
GOODWILL AND OTHER INTANGIBLE ASSETS
3 Months Ended
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets GOODWILL AND OTHER INTANGIBLE ASSETS
Dollars in MillionsEstimated Useful LivesMarch 31,
2022
December 31,
2021
Goodwill$20,500 $20,502 
Other intangible assets:
Licenses
5 – 15 years
307 307 
Acquired marketed product rights
3 – 15 years
60,477 60,454 
Capitalized software
3 – 10 years
1,544 1,499 
IPRD3,710 3,750 
Gross other intangible assets66,038 66,010 
Less accumulated amortization(25,935)(23,483)
Other intangible assets$40,103 $42,527 

Amortization expense of other intangible assets was $2.5 billion and $2.6 billion for the three months ended March 31, 2022 and 2021, respectively.

In the three months ended March 31, 2022, a $40 million IPRD impairment charge was recorded in Research and development expense following a decision to discontinue development of an investigational compound in connection with the prioritization of current pipeline opportunities. The compound was obtained in the acquisition of Celgene and was being studied as a potential treatment for autoimmune diseases. The charge represented a full write-down.

In the three months ended March 31, 2021, Inrebic EU regulatory approval milestones of $300 million were achieved resulting in a $385 million increase to the acquired marketed product rights intangible asset, after establishing the applicable deferred tax liability. An impairment charge of $315 million was recognized in Cost of products sold as the carrying value of this asset exceeded the projected undiscounted cash flows of the asset. The charge was equal to the excess of the asset's carrying value over its estimated fair value using discounted cash flow projections.
v3.22.1
SUPPLEMENTAL FINANCIAL INFORMATION
3 Months Ended
Mar. 31, 2022
Supplemental Financial Information [Abstract]  
Supplemental Financial Information SUPPLEMENTAL FINANCIAL INFORMATION
Dollars in MillionsMarch 31,
2022
December 31, 2021
Income taxes$2,182 $2,786 
Research and development604 514 
Contract assets410 361 
Equity investments228 255 
Restricted cash(a)
155 140 
Other959 776 
Other current assets$4,538 $4,832 

Dollars in MillionsMarch 31,
2022
December 31, 2021
Equity investments$2,185 $2,713 
Inventories843 909 
Operating leases894 919 
Pension and postretirement321 317 
Research and development319 248 
Restricted cash(a)
55 197 
Other228 232 
Other non-current assets$4,845 $5,535 
(a)    Restricted cash consists of funds restricted for annual Company contributions to the defined contribution plan in the U.S. and escrow for litigation settlements. Cash is restricted when withdrawal or general use is contractually or legally restricted.
Dollars in MillionsMarch 31,
2022
December 31, 2021
Rebates and discounts$5,455 $6,399 
Income taxes930 754 
Employee compensation and benefits662 1,375 
Research and development1,321 1,373 
Dividends1,151 1,186 
Interest356 378 
Royalties354 410 
Operating leases171 169 
Other1,955 1,927 
Other current liabilities$12,355 $13,971 

Dollars in MillionsMarch 31,
2022
December 31, 2021
Income taxes payable$4,889 $4,835 
Pension and postretirement625 654 
Operating leases852 874 
Deferred income319 326 
Deferred compensation409 427 
Other215 218 
Other non-current liabilities$7,309 $7,334 
v3.22.1
EQUITY
3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Equity EQUITY
The following table summarizes changes in equity for the three months ended March 31, 2022:
Common StockCapital in Excess of Par Value of StockAccumulated Other Comprehensive LossRetained EarningsTreasury StockNoncontrolling Interest
Dollars and Shares in MillionsSharesPar ValueSharesCost
Balance at December 31, 20212,923 $292 $44,361 $(1,268)$23,820 747 $(31,259)$60 
Net Earnings— — — — 1,278 — — 
Other Comprehensive Income— — — 39 — — — — 
Cash dividends declared(a)
— — — — (1,150)— — — 
Share repurchase program— — (750)— — 65 (4,250)— 
Stock compensation— — 145 — — (18)322 — 
Balance at March 31, 20222,923 $292 $43,756 $(1,229)$23,948 794 $(35,187)$65 
(a)    Cash dividends declared per common share were $0.54 for the three months ended March 31, 2022.

The following table summarizes changes in equity for the three months ended March 31, 2021:
Common StockCapital in Excess of Par Value of StockAccumulated Other Comprehensive LossRetained EarningsTreasury StockNoncontrolling Interest
Dollars and Shares in MillionsSharesPar ValueSharesCost
Balance at December 31, 20202,923 $292 $44,325 $(1,839)$21,281 679 $(26,237)$60 
Net Earnings— — — — 2,021 — — 
Other Comprehensive Income— — — 295 — — — — 
Cash dividends declared(a)
— — — — (1,098)— — — 
Share repurchase program— — — — — 28 (1,768)— 
Stock compensation— — (473)— — (15)806 — 
Balance at March 31, 20212,923 $292 $43,852 $(1,544)$22,204 692 $(27,199)$68 
(a)    Cash dividends declared per common share were $0.49 for the three months ended March 31, 2021.

BMS has a share repurchase program, authorized by its Board of Directors, allowing for repurchases of its shares. The share repurchase program does not obligate us to repurchase any specific number of shares, does not have a specific expiration date and may be suspended or discontinued at any time. Treasury stock is recognized at the cost to reacquire the shares. Shares issued from treasury are recognized utilizing the first-in first-out method.
The outstanding share repurchase authorization under the program was approximately $15.2 billion as of December 31, 2021. In the three months ended March, 31, 2022, BMS executed accelerated share repurchase ("ASR") agreements to repurchase an aggregate $5.0 billion of common stock. These ASR agreements were funded with cash on-hand and are expected to settle during the second and third quarters of 2022. Approximately 65 million shares of common stock (85% of the $5.0 billion aggregate repurchase price) were received by BMS and included in treasury stock. The total number of shares to be repurchased under the ASR agreements will be based on volume-weighted average prices of BMS's common stock during the terms of the ASR transactions less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreements. The remaining share repurchase capacity under the share repurchase program was approximately $10.2 billion as of March 31, 2022.

BMS repurchased 28 million shares of its common stock for $1.8 billion in the three months ended March 31, 2021.

The components of Other Comprehensive Income were as follows:
20222021
Dollars in MillionsPretaxTaxAfter TaxPretaxTaxAfter Tax
Three Months Ended March 31,
Derivatives qualifying as cash flow hedges:
Unrealized gains/(losses)$120 $(16)$104 $259 $(11)$248 
Reclassified to net earnings(a)
(85)12 (73)36 (4)32 
Derivatives qualifying as cash flow hedges35 (4)31 295 (15)280 
Pension and postretirement benefits:
Actuarial losses20 (4)16 21 (5)16 
Amortization(b)
(2)(3)
Settlements(b)
— — 
Pension and postretirement benefits27 (6)21 31 (8)23 
Marketable debt securities:
Unrealized (losses)/gains(2)(1)(3)(2)
Foreign currency translation(6)(6)(12)(15)(6)
Other Comprehensive Income$54 $(15)$39 $332 $(37)$295 
(a)Included in Cost of products sold.
(b)Included in Other (income)/expense, net.

The accumulated balances related to each component of Other Comprehensive Income, net of taxes, were as follows:
Dollars in MillionsMarch 31,
2022
December 31,
2021
Derivatives qualifying as cash flow hedges$209 $178 
Pension and postretirement benefits(747)(768)
Marketable debt securities
Foreign currency translation(692)(680)
Accumulated other comprehensive loss$(1,229)$(1,268)
v3.22.1
EMPLOYEE STOCK BENEFIT PLANS Employee Stock Benefit Plans (Notes)
3 Months Ended
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]  
Employee Stock Benefit Plans EMPLOYEE STOCK BENEFIT PLANS
Stock-based compensation expense was as follows:
 Three Months Ended March 31,
Dollars in Millions20222021
Cost of products sold$$15 
Marketing, selling and administrative48 60 
Research and development51 70 
Other (income)/expense, net— 
Total stock-based compensation expense$107 $151 
Income tax benefit(a)
$22 $31 
(a)    Income tax benefit excludes excess tax benefits from share-based compensation awards that were vested or exercised of $40 million and $17 million for the three months ended March 31, 2022 and 2021, respectively.

The number of units granted and the weighted-average fair value on the grant date for the three months ended March 31, 2022 were as follows:
Units in MillionsUnitsWeighted-Average Fair Value
Restricted stock units7.2 $63.13 
Market share units1.0 60.72 
Performance share units1.4 66.73 
Dollars in MillionsStock OptionsRestricted Stock UnitsMarket Share UnitsPerformance Share Units
Unrecognized compensation cost$$1,003 $90 $157 
Expected weighted-average period in years of compensation cost to be recognized0.43.13.42.2
v3.22.1
LEGAL PROCEEDINGS AND CONTINGENCIES
3 Months Ended
Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Legal Proceedings and Contingencies LEGAL PROCEEDINGS AND CONTINGENCIES
BMS and certain of its subsidiaries are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that BMS believes could become significant or material are described below.

While BMS does not believe that any of these matters, except as otherwise specifically noted below, will have a material adverse effect on its financial position or liquidity as BMS believes it has substantial defenses in the matters, the outcomes of BMS’s legal proceedings and other contingencies are inherently unpredictable and subject to significant uncertainties. There can be no assurance that there will not be an increase in the scope of one or more of these pending matters or any other or future lawsuits, claims, government investigations or other legal proceedings will not be material to BMS’s financial position, results of operations or cash flows for a particular period. Furthermore, failure to successfully enforce BMS’s patent rights would likely result in substantial decreases in the respective product revenues from generic competition.

Unless otherwise noted, BMS is unable to assess the outcome of the respective matters nor is it able to estimate the possible loss or range of losses that could potentially result for such matters. Contingency accruals are recognized when it is probable that a liability will be incurred and the amount of the related loss can be reasonably estimated. Developments in legal proceedings and other matters that could cause changes in the amounts previously accrued are evaluated each reporting period. For a discussion of BMS’s tax contingencies, see “—Note 7. Income Taxes”.
INTELLECTUAL PROPERTY

Anti-PD-1 and Anti-PD-L1 Antibody Litigation
In September 2015, Dana-Farber Cancer Institute (“Dana-Farber”) filed a complaint in the U.S. District Court for the District of Massachusetts seeking to correct the inventorship on up to six related U.S. patents directed to methods of treating cancer using PD-1 and PD-L1 antibodies. Specifically, Dana-Farber sought to add two scientists as inventors to these patents. In October 2017, Pfizer was allowed to intervene in the case alleging that one of the scientists identified by Dana-Farber was employed by a company eventually acquired by Pfizer during the relevant period. In May 2019, the District Court issued a decision ruling that the two scientists should be added as inventors to the patents which decision was affirmed on appeal. In June 2019, Dana-Farber filed a new lawsuit in the District of Massachusetts against BMS seeking damages as a result of the decision adding the scientists as inventors. In February 2021, BMS filed a motion to dismiss that complaint. In August 2021, the Court denied the motion to dismiss, but ruled that Dana-Farber’s claims for damages before May 17, 2019—the date of the District Court’s ruling that Dana-Farber was a co-inventor of the patents—are preempted by federal patent law. No trial date has been scheduled.

On March 17, 2022, BMS filed a lawsuit in U.S. District Court for the District of Delaware against AstraZeneca Pharmaceuticals LP and AstraZeneca UK Ltd ("AZ") alleging that AZ's marketing of the PD-L1 antibody Imfinzi infringes certain claims of U.S. Patent Nos. 9,580,505, 9,580,507, 10,138,299, 10,308,714, 10,266,594, 10,266,595, 10,266,596 and 10,323,092. No trial date has been scheduled.

CAR T
In October 2017, Juno and Sloan Kettering Institute for Cancer Research (“SKI”) filed a complaint for patent infringement against Kite Pharma, Inc. (“Kite”) in the U.S. District Court for the Central District of California. The complaint alleged that Kite’s Yescarta* product infringes certain claims of U.S. Patent No. 7,446,190 (the “’190 Patent”) concerning CAR T cell technologies. Kite filed an answer and counterclaims asserting non-infringement and invalidity of the ’190 Patent. In December 2019, following an eight-day trial, the jury rejected Kite’s defenses, finding that Kite willfully infringed the ’190 Patent and awarding to Juno and SKI a reasonable royalty consisting of a $585 million up-front payment and a 27.6% running royalty on Kite’s sales of Yescarta* through the expiration of the ’190 Patent in August 2024. In January 2020, Kite renewed its previous motion for judgment as a matter of law and also moved for a new trial, and Juno filed a motion seeking enhanced damages, supplemental damages, ongoing royalties, and prejudgment interest. In March 2020, the Court denied both of Kite’s motions in their entirety. In April 2020, the Court granted in part Juno’s motion and entered a final judgment awarding to Juno and SKI approximately $1.2 billion in royalties, interest and enhanced damages and a 27.6% running royalty on Kite’s sales of Yescarta* from December 13, 2019 through the expiration of the ’190 Patent in August 2024. In April 2020, Kite appealed the final judgment to the U.S. Court of Appeals for the Federal Circuit and the Court held an oral hearing on July 6, 2021. In August 2021, a Federal Circuit panel reversed the jury verdict and district court decision and found the ’190 Patent to be invalid. In October 2021, Juno and SKI filed a petition with the Federal Circuit for panel and en banc rehearing which the Federal Circuit denied on January 14, 2022. Juno and SKI intend to file a petition for a writ of certiorari with the U.S. Supreme Court.

Eliquis - Europe
In November 2020 and January 2021, Sandoz Limited (“Sandoz”) and Teva Pharmaceutical Industries Ltd. (“Teva Limited”), respectively, filed lawsuits in the United Kingdom seeking revocation of the UK apixaban composition of matter patent and related Supplementary Protection Certificate (“SPC”). BMS subsequently filed counterclaims for infringement in both actions. A trial took place in February 2022 and in a judgement issued on April 7, 2022, the judge found the UK apixaban composition of matter patent and related SPC invalid. We disagree with the ruling and plan to appeal the decision.

There are similar lawsuits filed in France, Italy, the Netherlands, Portugal, the Republic of Ireland, and Sweden seeking revocation of a composition of matter patent relating to Eliquis.

In April 2022, Sandoz informed BMS that it intends to launch its generic apixaban product in the Netherlands as soon as possible. In response, we have requested that the Dutch court issue a preliminary injunction to prevent any infringement of the Dutch apixaban composition of matter patent and related SPC as long as the patent and SPC are in force.

Additional infringement and invalidity actions involving Eliquis patents may be filed in various countries in Europe in the coming months.

Onureg – U.S.
In November 2021, BMS received a Notice Letter from Accord notifying BMS that Accord had filed an aNDA containing a paragraph IV certification seeking approval of a generic version of Onureg in the U.S. and challenging the one FDA Orange Book-listed formulation patent expiring in 2030. In response, BMS filed a patent infringement action against Accord in the U.S. District Court for the District of Delaware. No trial date has been scheduled.
Plavix* - Australia
Sanofi was notified that, in August 2007, GenRx Proprietary Limited (“GenRx”) obtained regulatory approval of an application for clopidogrel bisulfate 75mg tablets in Australia. GenRx, formerly a subsidiary of Apotex Inc., subsequently changed its name to Apotex (“GenRx-Apotex”). In August 2007, GenRx-Apotex filed an application in the Federal Court of Australia seeking revocation of Sanofi’s Australian Patent No. 597784 (Case No. NSD 1639 of 2007). Sanofi filed counterclaims of infringement and sought an injunction. On September 21, 2007, the Federal Court of Australia granted Sanofi’s injunction. A subsidiary of BMS was subsequently added as a party to the proceedings. In February 2008, a second company, Spirit Pharmaceuticals Pty. Ltd., also filed a revocation suit against the same patent. This case was consolidated with the GenRx-Apotex case. On August 12, 2008, the Federal Court of Australia held that claims of Patent No. 597784 covering clopidogrel bisulfate, hydrochloride, hydrobromide, and taurocholate salts were valid. The Federal Court also held that the process claims, pharmaceutical composition claims, and claim directed to clopidogrel and its pharmaceutically acceptable salts were invalid. BMS and Sanofi filed notices of appeal in the Full Court of the Federal Court of Australia (“Full Court”) appealing the holding of invalidity of the claim covering clopidogrel and its pharmaceutically acceptable salts, process claims, and pharmaceutical composition claims. GenRx-Apotex appealed. On September 29, 2009, the Full Court held all of the claims of Patent No. 597784 invalid. In March 2010, the High Court of Australia denied a request by BMS and Sanofi to hear an appeal of the Full Court decision. The case was remanded to the Federal Court for further proceedings related to damages sought by GenRx-Apotex. BMS and GenRx-Apotex settled, and the GenRx-Apotex case was dismissed. The Australian government intervened in this matter seeking maximum damages up to 449 million AUD ($337 million), plus interest, which would be split between BMS and Sanofi, for alleged losses experienced for paying a higher price for branded Plavix* during the period when the injunction was in place. BMS and Sanofi dispute that the Australian government is entitled to any damages. A trial was concluded in September 2017. In April 2020, the Federal Court issued a decision dismissing the Australian government’s claim for damages. In May 2020, the Australian government appealed the Federal Court’s decision and an appeal hearing concluded in February 2021.

Pomalyst - U.S.
In February 2022, Celgene received a Notice Letter from MSN Laboratories Pvt. Ltd. (“MSN”) notifying Celgene that MSN had filed an aNDA containing paragraph IV certifications seeking approval to market a generic version of Pomalyst in the U.S. In response, Celgene initiated a patent infringement action against MSN in the U.S. District Court for the District of New Jersey asserting certain FDA Orange Book-listed patents. No trial date has been scheduled.

Revlimid - U.S.
Celgene has received a Notice Letter from Alembic Pharmaceuticals Limited, Alembic Global Holding SA, and Alembic Pharmaceuticals, Inc. (“Alembic”) notifying Celgene that Alembic had filed an aNDA containing paragraph IV certifications seeking approval to market a generic version of Revlimid in the U.S. In response, Celgene initiated a patent infringement action against Alembic in the U.S. District Court for the District of New Jersey asserting certain FDA Orange Book-listed patents. Alembic has filed answers and counterclaims alleging that the asserted patents are invalid and/or not infringed. No trial date has been scheduled.

Sprycel - U.S.
In January 2022, BMS received a Notice Letter from Xspray Pharma AB ("Xspray") notifying BMS that Xspray had filed a 505(b)(2) NDA application containing paragraph IV certifications seeking approval of a dasatinib product in the U.S. and challenging two FDA Orange Book-listed monohydrate form patents expiring in 2025 and 2026. In February 2022, BMS filed a patent infringement action against Xspray in the U.S. District Court for the District of New Jersey. No trial date has been scheduled.

Zeposia - U.S.
On October 15, 2021, Actelion Pharmaceuticals LTD and Actelion Pharmaceuticals US, INC (“Actelion”), filed a complaint for patent infringement in the United States District Court for the District of New Jersey against BMS and Celgene for alleged infringement of U.S. Patent No. 10,251,867 (the “’867 Patent”). The Complaint alleges that the sale of Zeposia infringes certain claims of the ’867 Patent and Actelion is seeking damages and injunctive relief. No trial date has been scheduled.

PRICING, SALES AND PROMOTIONAL PRACTICES LITIGATION

Plavix* State Attorneys General Lawsuits
BMS and certain Sanofi entities are defendants in consumer protection actions brought by the attorneys general of Hawaii and New Mexico relating to the labeling, sales and/or promotion of Plavix*. A trial in the Hawaii matter occurred in 2020. In February 2021, the Court issued a decision against Sanofi and BMS, imposing penalties in the total amount of $834 million, with $417 million attributed to BMS. Sanofi and BMS disagree with the decision and are appealing it. BMS remains confident in the merits of its case and its likelihood of success on appeal and BMS does not believe establishing a reserve is warranted for this matter. A trial in the New Mexico matter was previously scheduled for April 2022, but was adjourned due to statewide trial delays arising from the COVID-19 pandemic. Trial has been rescheduled for January 2023.
PRODUCT LIABILITY LITIGATION

BMS is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. As previously disclosed, in addition to lawsuits, BMS also faces unfiled claims involving its products.

Abilify*
BMS and Otsuka are co-defendants in product liability litigation related to Abilify*. Plaintiffs allege Abilify* caused them to engage in compulsive gambling and other impulse control disorders. There have been over 2,500 cases filed in state and federal courts and additional cases are pending in Canada. The Judicial Panel on Multidistrict Litigation consolidated the federal court cases for pretrial purposes in the U.S. District Court for the Northern District of Florida. In February 2019, BMS and Otsuka entered into a master settlement agreement establishing a proposed settlement program to resolve all Abilify* compulsivity claims filed as of January 28, 2019 in the MDL as well as various state courts, including California and New Jersey. To date, approximately 2,700 cases, comprising approximately 3,900 plaintiffs, have been dismissed based on participation in the settlement program or failure to comply with settlement related court orders. In the U.S., less than five cases remain pending in state or federal courts (New Jersey and Massachusetts). There are eleven cases pending in Canada (four class actions, seven individual injury claims). Out of the eleven cases, only two are active (the class actions in Quebec and Ontario). Both class actions have now been certified and will proceed separately, subject to a potential further appeal of the Ontario class certification decision.

Byetta*
Amylin, a former subsidiary of BMS, and Lilly are co-defendants in product liability litigation related to Byetta*. This litigation involved lawsuits on behalf of plaintiffs, which include injury plaintiffs as well as claims by spouses and/or other beneficiaries, in various courts in the U.S. The majority of these cases have been brought by individuals who allege personal injury sustained after using Byetta*, primarily pancreatic cancer, and, in some cases, claiming alleged wrongful death. The majority of cases are pending in Federal Court in San Diego in an MDL or in a coordinated proceeding in California Superior Court in Los Angeles (“JCCP”). In April 2020 the defendants filed a motion for summary judgment based on federal preemption and a motion for summary judgment based on the absence of general causation evidence in the MDL and JCCP. Both motions were granted in March 2021 and April 2021, respectively. The orders will result in the dismissal of all claims alleging an injury of pancreatic cancer in the MDL and JCCP. Plaintiffs initially appealed the MDL order, but subsequently filed a motion to dismiss their appeal as to Amylin and Lilly. That motion to dismiss was granted on October 5, 2021 making the MDL decision final as to Amylin and Lilly. Plaintiffs may seek appeals in the JCCP. As of March 2022, Plaintiffs’ counsel have submitted dismissals with prejudice in exchange for a waiver of costs on behalf of approximately 75% of the plaintiffs in the JCCP (including injury plaintiffs and spouse/beneficiary plaintiffs) alleging claims against Amylin and Lilly. Additional dismissals are anticipated. BMS sold Byetta* to AstraZeneca in February 2014 as part of BMS’s global diabetes business divestiture and any additional liability to Amylin with respect to Byetta* is expected to be shared with AstraZeneca.

Onglyza*
BMS and AstraZeneca are co-defendants in product liability litigation related to Onglyza*. Plaintiffs assert claims, including claims for wrongful death, as a result of heart failure or other cardiovascular injuries they allege were caused by their use of Onglyza*. As of April 2022, claims are pending in federal and NY state court on behalf of approximately 252 individuals who allege they ingested the product and suffered an injury. In February 2018, the Judicial Panel on Multidistrict Litigation ordered all federal cases to be transferred to an MDL in the U.S. District Court for the Eastern District of Kentucky. A significant majority of the claims are pending in the MDL, with others pending in a coordinated proceeding in California Superior Court in San Francisco (“JCCP”). In August 2021, the MDL and JCCP courts jointly heard evidence regarding the parties’ motions to exclude general causation experts. On September 24, 2021, the JCCP court granted defendants’ motion to exclude plaintiffs’ only general causation expert and largely denied plaintiffs’ motions to exclude defendants’ general causation experts; on January 5, 2022, the MDL court likewise granted defendants’ motion to exclude plaintiffs’ expert and denied entirely plaintiffs’ motions. On March 30, 2022, the JCCP court granted summary judgment to defendants, thus effectively dismissing the 18 claims previously pending in California state court. As part of BMS’s global diabetes business divestiture, BMS sold Onglyza* to AstraZeneca in February 2014 and any potential liability with respect to Onglyza* is expected to be shared with AstraZeneca.
SECURITIES LITIGATION

BMS Securities Class Action
Since February 2018, two separate putative class action complaints were filed in the U.S. District for the Northern District of California and in the U.S. District Court for the Southern District of New York against BMS, BMS’s Chief Executive Officer, Giovanni Caforio, BMS’s Chief Financial Officer at the time, Charles A. Bancroft and certain former and current executives of BMS. The case in California was voluntarily dismissed. The remaining complaint alleged violations of securities laws for BMS’s disclosures related to the CheckMate-026 clinical trial in lung cancer. In September 2019, the Court granted BMS’s motion to dismiss, but allowed the plaintiffs leave to file an amended complaint. In October 2019, the plaintiffs filed an amended complaint. In September 2020, the Court granted BMS’s motion to dismiss the amended complaint with prejudice. The plaintiffs appealed the Court’s decision in October 2020. On March 11, 2022, the Second Circuit affirmed the dismissal with prejudice of the amended complaint.

Celgene Securities Litigations
Beginning in March 2018, two putative class actions were filed against Celgene and certain of its officers in the U.S. District Court for the District of New Jersey (the “Celgene Securities Class Action”). The complaints allege that the defendants violated federal securities laws by making misstatements and/or omissions concerning (1) trials of GED-0301, (2) Celgene’s 2020 outlook and projected sales of Otezla*, and (3) the new drug application for Zeposia. The Court consolidated the two actions and appointed a lead plaintiff, lead counsel, and co-liaison counsel for the putative class. In February 2019, the defendants filed a motion to dismiss plaintiff’s amended complaint in full. In December 2019, the Court denied the motion to dismiss in part and granted the motion to dismiss in part (including all claims arising from alleged misstatements regarding GED-0301). Although the Court gave the plaintiff leave to re-plead the dismissed claims, it elected not to do so, and the dismissed claims are now dismissed with prejudice. In November 2020, the Court granted class certification with respect to the remaining claims.

In April 2020, certain Schwab management investment companies on behalf of certain Schwab funds filed an individual action in the U.S. District Court for the District of New Jersey asserting largely the same allegations as the Celgene Securities Class Action against the same remaining defendants in that action (the “Schwab Action”). In July 2020, the defendants filed a motion to dismiss the plaintiffs’ complaint in full. In March 2021, the Court granted in part and denied in part defendants’ motion to dismiss consistent with its decision in the Celgene Securities Class Action.

The California Public Employees’ Retirement System in April 2021 (the “CalPERS Action”); DFA Investment Dimensions Group Inc., on behalf of certain of its funds; and American Century Mutual Funds, Inc., on behalf of certain of its funds, in July 2021 (respectively the “DFA Action” and the “American Century Action”), and GIC Private Limited in September 2021 (the “GIC Action”), filed separate individual actions in the U.S. District Court for the District of New Jersey asserting largely the same allegations as the Celgene Securities Class Action and the Schwab individual action against the same remaining defendants in those actions. In October 2021, these actions were consolidated for pre-trial proceedings with the Schwab Action. The court also consolidated any future direct actions raising common questions of law and fact with the Schwab Action.

No trial dates have been scheduled in any of the above Celgene Securities Litigations.

Contingent Value Rights Litigations
In June 2021, an action was filed against BMS in the U.S. District Court for the Southern District of New York asserting claims of alleged breaches of a Contingent Value Rights Agreement (“CVR Agreement”) entered into in connection with the closing of BMS’s acquisition of Celgene Corporation in November 2019. The successor trustee under the CVR Agreement alleges that BMS breached the CVR Agreement by allegedly failing to use “diligent efforts” to obtain FDA approval of liso-cel (Breyanzi) before a contractual milestone date, thereby avoiding a $6.4 billion potential obligation to holders of the contingent value rights governed by the CVR Agreement and by allegedly failing to permit inspection of records in response to a request by the successor trustee. The successor trustee seeks damages in an amount to be determined at trial and other relief, including interest and attorneys’ fees. BMS disputes the successor trustee’s allegations and filed a Motion to Dismiss on July 23, 2021. All discovery is stayed until there is a decision on the Motion to Dismiss.
In October 2021, alleged former Celgene stockholders filed a complaint in the U.S. District Court for the Southern District of New York asserting claims on behalf of a putative class of Celgene stockholders who received CVRs in the BMS merger with Celgene for violations of sections 14(a) and 20(a) of the Securities Exchange Act of 1934 relating to the joint proxy statement. That action later was consolidated with another action filed in the same court asserting claims on behalf of a class of CVR acquirers, whether in the BMS merger with Celgene or otherwise, for violations of sections 11, 12(a)(2), and 15 of the Securities Act of 1933 and sections 10(b), 14(a) and 20(2) of the Securities Exchange Act of 1934. In asserting claims on behalf of a putative class of Celgene stockholders who received CVRs in the merger and persons who purchased CVRs for violations of sections 11, 12(a)(2), and 15 of the Securities Act of 1933 and sections 10(b), 14(a), and 20(a) of the Securities Exchange Act of 1934. The complaint alleges that the February 22, 2019 joint proxy statement was materially false or misleading because it failed to disclose that BMS allegedly had no intention to obtain FDA approval for liso-cel (Breyanzi) by the applicable milestone date in the CVR Agreement and that certain statements made by BMS or certain BMS officers in periodic SEC filings, earnings calls, press releases, and investor presentations between December 2019 and November 2020 were materially false or misleading for the same reason. Defendants have moved to dismiss the complaint.

In November 2021, an alleged purchaser of CVRs filed a complaint in the Supreme Court of the State of New York for New York County asserting claims on behalf of a putative class of CVR acquirers for violations of sections 11(a) and 12(a)(2) of the Securities Act of 1933. The complaint alleges that the registration statement filed in connection with the proposed merger transaction between Celgene and BMS was materially false or misleading because it failed to disclose that allegedly BMS had no intention at the time to obtain FDA approval for liso-cel (Breyanzi) by the contractual milestone date. The complaint asserts claims against BMS, the members of its board of directors at the time of the joint proxy statement, and certain BMS officers who signed the registration statement. BMS removed the action to the U.S. District Court for the Southern District of New York. The plaintiff has filed a motion to remand the action to the state court.

In November 2021, an alleged Celgene stockholder filed a complaint in the Superior Court of New Jersey, Union County asserting claims on behalf of two separate putative classes, one of acquirers of CVRs and one of acquirers of BMS common stock, for violations of sections 11(a), 12(a)(2), and 15 of the Securities Act of 1933. The complaint alleges that the registration statement filed in connection with the proposed merger transaction between Celgene and BMS was materially false or misleading because it failed to disclose that allegedly BMS had no intention at the time to obtain FDA approval for liso-cel (Breyanzi) by the contractual milestone date. The complaint asserts claims against BMS, the members of its board of directors at the time of the joint proxy statement, certain BMS officers who signed the registration statement and Celgene’s former chairman and chief executive officer. BMS removed the action to the U.S. District Court for the District of New Jersey and filed a motion to transfer the action to the U.S. District Court for the Southern District of New York. The plaintiff has filed a motion to remand the action to the state court.

No trial dates have been scheduled in any of the above CVR Litigations.

OTHER LITIGATION

HIV Medication Antitrust Litigations
BMS and two other manufacturers of HIV medications are defendants in related lawsuits pending in the Northern District of California. The lawsuits, filed on behalf of indirect purchasers, allege that the defendants’ agreements to develop and sell fixed-dose combination products for the treatment of HIV, including Atripla* and Evotaz®, violate antitrust laws. In July 2020, the Court granted in part defendants’ motion to dismiss, including dismissing with prejudice plaintiffs’ claims as to an overarching conspiracy and plaintiffs’ theories based on the alleged payment of royalties after patent expiration. Other claims, however, remain. In September and October 2020, two purported class actions were also filed asserting similar claims on behalf of direct purchasers. In March 2021, the Court dismissed one of the direct purchaser cases and limited the claims of the remaining direct purchaser case to those arising in 2016 or later. However, the Court gave plaintiffs leave to amend their complaints, and one plaintiff filed an amended complaint on March 16, 2021. On September 22, 2021, two additional non-class action direct purchaser complaints were filed by a number of retail pharmacy and grocery store chains against BMS and two other manufacturers of HIV medications. These complaints make allegations similar to those raised in the other federal court cases and the New Mexico state court case described below. In October 2021 and March 2022, BMS entered into settlement agreements with the putative class of indirect purchasers and the putative class of direct purchasers, respectively. Both settlements are subject to court approval. In January 2022, BMS reached an agreement to settle the cases filed against it by the retail pharmacy and grocery store chains.

In February 2021, BMS and two other manufacturers of HIV medications were sued in State Court in New Mexico by the Attorney General of the State of New Mexico in a case alleging that the defendants’ agreements to develop and sell various fixed-dose combination products for the treatment of HIV, including Atripla*, and agreements to settle certain patent litigation violate the antitrust laws of the State of New Mexico. No trial date has been scheduled.
In December 2021, five additional non-class-action indirect purchaser cases were filed in the Northern District of California, and one additional non-class-action indirect purchaser case was filed in California state court naming BMS and two other manufacturers as defendants. These complaints make allegations similar to those in the other federal court cases. In February 2022, BMS reached a settlement agreement with one of the non-class-action indirect purchaser plaintiffs and in April 2022, two additional indirect purchaser plaintiffs filed non-class suits against BMS and other defendants. In total, there are now seven non-class action indirect purchaser cases pending against BMS among others. No trial date has been scheduled for these remaining cases.

Thalomid and Revlimid Litigations
Beginning in November 2014, certain putative class action lawsuits were filed against Celgene in the U.S. District Court for the District of New Jersey alleging that Celgene violated various antitrust, consumer protection, and unfair competition laws by (a) allegedly securing an exclusive supply contract for the alleged purpose of preventing a generic manufacturer from securing its own supply of thalidomide active pharmaceutical ingredient, (b) allegedly refusing to sell samples of Thalomid and Revlimid brand drugs to various generic manufacturers for the alleged purpose of bioequivalence testing necessary for aNDAs to be submitted to the FDA for approval to market generic versions of these products, (c) allegedly bringing unjustified patent infringement lawsuits in order to allegedly delay approval for proposed generic versions of Thalomid and Revlimid, and/or (d) allegedly entering into settlements of patent infringement lawsuits with certain generic manufacturers that allegedly have had anticompetitive effects. The plaintiffs, on behalf of themselves and putative classes of third-party payers, sought injunctive relief and damages. The various lawsuits were consolidated into a master action for all purposes. In March 2020, Celgene reached a settlement with the class plaintiffs. In October 2020, the Court entered a final order approving the settlement and dismissed the matter. That settlement did not resolve the claims of certain entities that opted out of the settlement.

In May 2018, Humana, Inc. (“Humana”) filed a lawsuit against Celgene in the Pike County Circuit Court of the Commonwealth of Kentucky. Humana’s complaint alleges Celgene engaged in unlawful off-label marketing in connection with sales of Thalomid and Revlimid and asserts claims against Celgene for fraud, breach of contract, negligent misrepresentation, unjust enrichment and violations of New Jersey’s Racketeer Influenced and Corrupt Organizations Act. Humana subsequently dismissed its claims for breach of contract voluntarily. The complaint seeks, among other things, treble and punitive damages, injunctive relief and attorneys’ fees and costs. A trial has been scheduled for January 2023.

In March 2019, Humana filed a lawsuit against Celgene in the U.S. District Court for the District of New Jersey. Humana’s complaint makes largely the same claims and allegations as were made in the Thalomid and Revlimid antitrust class action litigation. The complaint purports to assert claims on behalf of Humana and its subsidiaries in several capacities, including as a direct purchaser and as an indirect purchaser, and seeks, among other things, treble and punitive damages, injunctive relief and attorneys’ fees and costs. In May 2019, Celgene filed a motion to dismiss Humana’s complaint, and the Court has stayed discovery pending adjudication of that motion. No trial date has been scheduled.

In March 2020, United HealthCare Services, Inc. (“UHS”), affiliates of which opted out of the first settlement in the Thalomid and Revlimid antitrust class action litigation, filed a lawsuit against Celgene in the U.S. District Court for the District of Minnesota. UHS’s complaint makes largely the same claims and allegations as were made in the class action litigation in addition to certain claims regarding donations directed to copay assistance. The complaint purports to assert claims on behalf of UHS and its subsidiaries in several capacities, including as a direct purchaser and as an indirect purchaser, and seeks, among other things, treble and punitive damages, injunctive relief and attorneys’ fees and costs. In December 2020, Celgene’s motion to transfer the action to the District of New Jersey was granted and the case is now pending in that Court. In January 2021, Celgene filed a motion to dismiss UHS’s complaint, which the Court administratively terminated in June 2021 pending its decision on Celgene’s pending motion to dismiss Humana’s complaint. No trial date has been scheduled.

In May 2020, Celgene filed suit against Humana Pharmacy, Inc. (“HPI”), a Humana subsidiary, in Delaware Superior Court. Celgene’s complaint alleges that HPI breached its contractual obligations to Celgene by assigning claims to Humana that Humana is now asserting. The complaint seeks damages for HPI’s breach as well as a declaratory judgment. A trial has been scheduled for March 2023.

In July 2020, Blue Cross Blue Shield Association (“BCBSA”) sued Celgene and BMS on behalf of the Federal Employee Program in the U.S. District Court for the District of Columbia. BCBSA’s complaint makes largely the same claims and allegations as were made in the class action litigation. In April 2021, the parties’ joint motion to transfer the action to the District of New Jersey was granted and the case is now pending in that Court. No trial date has been scheduled.
In August 2020, BCBSM Inc., Health Care Service Corporation (“HCSC”), Blue Cross and Blue Shield of Florida Inc., and Molina Healthcare, Inc. (“Molina”) sued Celgene and BMS in a Minnesota state court. The complaint makes largely the same claims and allegations as were made in the class action litigation but adds allegations on behalf of HCSC only as to alleged off-label marketing of Thalomid and Revlimid. In September 2020, Celgene and BMS removed the action to the U.S. District Court for the District of Minnesota. In March 2021, that Court denied plaintiffs’ motion to remand the action to state court, dismissed Molina for lack of personal jurisdiction and granted defendants’ motion to transfer the action to the District of New Jersey. The case is now pending in the District of New Jersey. No trial date has been scheduled.

In January 2021, Cigna Corporation (“Cigna”) sued Celgene and BMS in the U.S. District Court for the Eastern District of Pennsylvania. Cigna’s complaint makes largely the same claims and allegations as were made in the class action litigation. Cigna’s complaint purports to assert claims on behalf of Cigna and its subsidiaries in several capacities, including as a direct purchaser and as an indirect purchaser. In May 2021, the parties’ joint motion to transfer the action to the District of New Jersey was granted and the case is now pending in that Court. No trial date has been scheduled.

In May 2021, Molina sued Celgene and BMS in San Francisco Superior Court. Molina’s complaint makes largely the same claims and allegations as were made in the class action litigation. In July 2021, Celgene and BMS removed the action to the U.S. District Court for the Northern District of California, and in January 2022, that court granted Molina’s motion to remand to San Francisco Superior Court. No trial date has been scheduled.

In December 2021, a group of plaintiffs—MSP Recovery Claims, Series LLC; MSPA Claims 1, LLC; MAO-MSO Recovery II, LLC, Series PMPI, a segregated series of MAO-MSO Recovery II, LLC; MSP Recovery Claims Series 44, LLC; MSP Recovery Claims PROV, Series LLC; and MSP Recovery Claims CAID, Series LLC (together, “MSP”)—sued Celgene and BMS in the U.S. District Court for the District of New Jersey. MSP’s complaint makes largely the same claims and allegations as were made in the class action litigation. MSP purports to pursue assignments from certain named and unnamed entities that allegedly purchased or otherwise provided reimbursement for Thalomid and/or Revlimid, and purports to bring direct and indirect purchaser claims. In February 2022, MSP filed an amended complaint, adding claims arising from the Company's donations to charitable organizations, and adding those organizations as defendants. No trial date has been scheduled.

BeiGene Arbitration Matter
On July 5, 2017, Celgene Logistics Sàrl (“Celgene Logistics”) and BeiGene, Ltd. (together with its assignees, “BeiGene”), entered into a License and Supply Agreement (the “LSA”) pursuant to which BeiGene was granted, among other things, an exclusive license to distribute and commercialize Revlimid, Vidaza and Abraxane in China.

As has been disclosed publicly, BeiGene initiated an arbitration proceeding against Celgene Logistics and BMS at the International Chamber of Commerce in June 2020, asserting various claims, including breach of contract under the LSA. In October 2021, Celgene Logistics delivered notice to BeiGene terminating the LSA with respect to Abraxane.

MSK Contract Litigation
On April 1, 2022, Memorial Sloan Kettering Cancer Center and Eureka Therapeutics, Inc. (collectively, “Plaintiffs”) filed a complaint against BMS, Celgene and Juno (collectively, “Defendants”) alleging that Defendants breached a license agreement by allegedly failing to use commercially reasonable efforts to develop, manufacture, and commercialize a certain chimeric antigen receptor product and by failing to pay Plaintiffs a running royalty of at least 1.5% of worldwide sales of Abecma allegedly owed to Plaintiffs under the license agreement. Defendants disagree with plaintiffs’ claims. No trial date has been scheduled.

GOVERNMENT INVESTIGATIONS

Like other pharmaceutical companies, BMS and certain of its subsidiaries are subject to extensive regulation by national, state and local authorities in the U.S. and other countries in which BMS operates. As a result, BMS, from time to time, is subject to various governmental and regulatory inquiries and investigations as well as threatened legal actions and proceedings. It is possible that criminal charges, substantial fines and/or civil penalties, could result from government or regulatory investigations.

ENVIRONMENTAL PROCEEDINGS

As previously reported, BMS is a party to several environmental proceedings and other matters, and is responsible under various state, federal and foreign laws, including CERCLA, for certain costs of investigating and/or remediating contamination resulting from past industrial activity at BMS’s current or former sites or at waste disposal or reprocessing facilities operated by third parties.
CERCLA Matters

With respect to CERCLA matters for which BMS is responsible under various state, federal and international laws, BMS typically estimates potential costs based on information obtained from the U.S. Environmental Protection Agency, or counterpart state or foreign agency and/or studies prepared by independent consultants, including the total estimated costs for the site and the expected cost-sharing, if any, with other “potentially responsible parties,” and BMS accrues liabilities when they are probable and reasonably estimable. BMS estimated its share of future costs for these sites to be $89 million at March 31, 2022, which represents the sum of best estimates or, where no best estimate can reasonably be made, estimates of the minimal probable amount among a range of such costs (without taking into account any potential recoveries from other parties). The amount includes the estimated costs for any additional probable loss associated with the previously disclosed North Brunswick Township High School Remediation Site.
v3.22.1
BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING STANDARDS (Policies)
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Basis of Consolidation
Basis of Consolidation

Bristol-Myers Squibb Company (“BMS” or “the Company”) prepared these unaudited consolidated financial statements following the requirements of the SEC and U.S. GAAP for interim reporting. Under those rules, certain footnotes and other financial information that are normally required for annual financial statements can be condensed or omitted. The Company is responsible for the consolidated financial statements included in this Quarterly Report on Form 10-Q, which include all adjustments necessary for a fair presentation of the financial position at March 31, 2022 and December 31, 2021 and the results of operations and cash flows for the three months ended March 31, 2022 and 2021. All intercompany balances and transactions have been eliminated. These financial statements and the related notes should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2021 included in the 2021 Form 10-K. Refer to the Summary of Abbreviated Terms at the end of this Quarterly Report on Form 10-Q for terms used throughout the document.
Business Segment Information
Business Segment Information

BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the discovery, development, manufacturing and supply of products. Regional commercial organizations market, distribute and sell the products. The business is also supported by global corporate staff functions. Consistent with BMS’s operational structure, the Chief Executive Officer (“CEO”), as the chief operating decision maker, manages and allocates resources at the global corporate level. Managing and allocating resources at the global corporate level enables the CEO to assess both the overall level of resources available and how to best deploy these resources across functions, therapeutic areas, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or franchise basis. The determination of a single segment is consistent with the financial information regularly reviewed by the CEO for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods. For further information on product and regional revenue, see “—Note 2. Revenue”.
Use of Estimates and Judgements
Use of Estimates and Judgments

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Accordingly, the results and trends in these unaudited consolidated financial statements may not be indicative of full year operating results. The preparation of financial statements requires the use of management estimates, judgments and assumptions. The most significant assumptions are estimates used in determining accounting for acquisitions; impairments of goodwill and intangible assets; chargebacks, cash discounts, sales rebates, returns and other adjustments; legal contingencies; and income taxes. Actual results may differ from estimates.
Reclassifications
Reclassifications

Certain reclassifications were made to conform the prior period consolidated financial statements to the current period presentation. Up-front and contingent milestone charges in connection with asset acquisitions or licensing of third-party intellectual property rights previously presented in Research and development are now presented in Acquired IPRD in the consolidated statement of earnings. Proceeds received from the sale of equity investment securities previously presented in Divestiture and other proceeds in the consolidated statements of cash flows is now presented separately in Proceeds from sales of equity investment securities. Additionally, Rebates and discounts previously presented in Other changes in operating assets and liabilities in the consolidated statements of cash flows is now presented separately in Rebates and discounts.
Recently Issued Accounting Standards Not Yet Adopted
Recently Issued Accounting Standards Not Yet Adopted

Business Combinations

In October 2021, the FASB issued amended guidance on accounting for contract assets and contract liabilities from contracts with customers in a business combination. The guidance is intended to address inconsistency related to recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized. At the acquisition date, an entity should account for the related revenue contracts in accordance with existing revenue recognition guidance generally by assessing how the acquiree applied recognition and measurement in their financial statements. The amended guidance is effective January 1, 2023 on a prospective approach. Early adoption is permitted.
Collaboration Arrangements BMS enters into collaboration arrangements with third parties for the development and commercialization of certain products. Although each of these arrangements is unique in nature, both parties are active participants in the operating activities of the collaboration and exposed to significant risks and rewards depending on the commercial success of the activities. BMS may either in-license intellectual property owned by the other party or out-license its intellectual property to the other party. These arrangements also typically include research, development, manufacturing, and/or commercial activities and can cover a single investigational compound or commercial product or multiple compounds and/or products in various life cycle stages. The rights and obligations of the parties can be global or limited to geographic regions. BMS refers to these collaborations as alliances and its partners as alliance partners.
v3.22.1
Revenue (Tables)
3 Months Ended
Mar. 31, 2022
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The following table summarizes the disaggregation of revenue by nature:
Three Months Ended March 31,
Dollars in Millions20222021
Net product sales$11,308 $10,798 
Alliance revenues188 142 
Other revenues152 133 
Total Revenues$11,648 $11,073 
Revenue Recognition Gross-To-Net Adjustments
The following table summarizes GTN adjustments:
Three Months Ended March 31,
Dollars in Millions20222021
Gross product sales$16,650 $15,559 
GTN adjustments(a)
Charge-backs and cash discounts(1,763)(1,586)
Medicaid and Medicare rebates(2,084)(1,718)
Other rebates, returns, discounts and adjustments(1,495)(1,457)
Total GTN adjustments(5,342)(4,761)
Net product sales$11,308 $10,798 
(a)    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $74 million and $217 million for the three months ended March 31, 2022, and 2021, respectively.
Revenue from External Customers by Products and Services
The following table summarizes the disaggregation of revenue by product and region:
Three Months Ended March 31,
Dollars in Millions20222021
In-Line Products
Eliquis$3,211 $2,886 
Opdivo1,923 1,720 
Pomalyst/Imnovid826 773 
Orencia792 758 
Sprycel483 470 
Yervoy515 456 
Empliciti75 85 
Mature and other products462 506 
New Product Portfolio
Reblozyl156 112 
Abecma67 — 
Zeposia36 18 
Breyanzi44 — 
Inrebic18 16 
Onureg23 15 
Opdualag— 
Recent LOE Products(a)
Revlimid2,797 2,944 
Abraxane214 314 
Total Revenues$11,648 $11,073 
United States$7,694 $7,010 
Europe2,413 2,553 
Rest of the World1,314 1,346 
Other(b)
227 164 
Total Revenues$11,648 $11,073 
(a)    Recent LOE Products includes products with significant decline in revenue from the prior reporting period as a result of a loss of exclusivity.
(b)    Other revenues include royalties and alliance-related revenues for products not sold by BMS’s regional commercial organizations.
v3.22.1
ALLIANCES (Tables)
3 Months Ended
Mar. 31, 2022
ALLIANCES [Abstract]  
Collaborative Arrangement and Arrangement Other than Collaborative
Selected financial information pertaining to alliances was as follows, including net product sales when BMS is the principal in the third-party customer sale for products subject to the alliance. Expenses summarized below do not include all amounts attributed to the activities for the products in the alliance, but only the payments between the alliance partners or the related amortization if the payments were deferred or capitalized.
Three Months Ended March 31,
Dollars in Millions20222021
Revenues from alliances:
Net product sales$3,239 $2,882 
Alliance revenues188 142 
Total Revenues$3,427 $3,024 
Payments to/(from) alliance partners:
Cost of products sold$1,556 $1,397 
Marketing, selling and administrative(54)(49)
Research and development22 
Other (income)/expense, net(12)(5)
Dollars in MillionsMarch 31,
2022
December 31,
2021
Selected Alliance Balance Sheet information:
Receivables – from alliance partners$304 $320 
Accounts payable – to alliance partners1,504 1,229 
Deferred income from alliances(a)
326 330 
(a)    Includes unamortized upfront and milestone payments.
v3.22.1
DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS (Tables)
3 Months Ended
Mar. 31, 2022
Acquisitions, Divestitures and Other Arrangements [Abstract]  
Disposal Groups, Including Discontinued Operations
The following table summarizes the financial impact of divestitures including royalties, which are included in Other (income)/expense, net. Revenue and pretax earnings related to all divestitures were not material in all periods presented (excluding divestiture gains or losses).
Three Months Ended March 31,
Net Proceeds(a)
Divestiture (Gains)/LossesRoyalty Income
Dollars in Millions202220212022202120222021
Diabetes Business$172 $164 $— $— $(170)$(134)
Mature Products and Other225 16 (211)— (1)(1)
Total$397 $180 $(211)$— $(171)$(135)
(a)    Includes royalties received subsequent to the related sale of the asset or business.
Licensing and Other Arrangements
The following table summarizes the financial impact of Keytruda* royalties, Tecentriq* royalties, up-front licensing fees and milestones for products that have not obtained commercial approval, which are included in Other (income)/expense, net.
Three Months Ended March 31,
Dollars in Millions20222021
Keytruda* royalties
$(221)$(192)
Tecentriq* royalties
(25)(22)
Contingent milestone income(41)— 
Amortization of deferred income(12)(15)
Other royalties(7)(3)
Total$(306)$(232)
v3.22.1
OTHER (INCOME)/EXPENSE, NET (Tables)
3 Months Ended
Mar. 31, 2022
Other Nonoperating Income (Expense) [Abstract]  
Schedule Of Other Income Expense
Three Months Ended March 31,
Dollars in Millions20222021
Interest expense$326 $353 
Royalties and licensing income(477)(367)
Equity investment losses/(gains)644 (601)
Integration expenses105 141 
Contingent consideration(510)
Loss on debt redemption275 281 
Provision for restructuring23 45 
Litigation and other settlements(37)(8)
Transition and other service fees(1)(15)
Investment income(10)(9)
Divestiture gains(211)— 
Other11 (12)
Other (income)/expense, net$649 $(702)
v3.22.1
RESTRUCTURING (Tables)
3 Months Ended
Mar. 31, 2022
Restructuring Cost and Reserve [Line Items]  
Restructuring and Related Costs
The following provides the charges related to restructuring initiatives by type of cost:
Three Months Ended March 31,
Dollars in Millions20222021
Celgene Acquisition Plan$127 $173 
MyoKardia Acquisition Plan37 
Total charges$130 $210 
Employee termination costs$22 $44 
Other termination costs
Provision for restructuring23 45 
Integration expenses105 141 
Accelerated depreciation— 
Asset impairments— 24 
Total charges$130 $210 
Cost of products sold$— $24 
Marketing, selling and administrative— 
Other (income)/expense, net128 186 
Total charges$130 $210 
Schedule of Restructuring Reserve by Type of Cost
The following summarizes the charges and spending related to restructuring plan activities:
Three Months Ended March 31,
Dollars in Millions20222021
Liability at December 31$101 $148 
Provision for restructuring(a)
23 39 
Foreign currency translation and other(1)(2)
Payments(21)(59)
Liability at March 31
$102 $126 
(a)    Includes a reduction of the liability resulting from changes in estimates of $9 million and $1 million for the three months ended March 31, 2022 and 2021, respectively. Excludes $6 million for the three months ended March 31, 2021 of accelerated stock-based compensation relating to the Celgene Acquisition Plan.
v3.22.1
INCOME TAXES (Tables)
3 Months Ended
Mar. 31, 2022
Income Tax Disclosure [Abstract]  
Schedule of Provision for Income Taxes
Three Months Ended March 31,
Dollars in Millions20222021
Earnings Before Income Taxes$1,687 $2,530 
Provision for Income Taxes404 501 
Effective Tax Rate23.9 %19.8 %
v3.22.1
EARNINGS PER SHARE (Tables)
3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
Schedule of Earnings/(Loss) Per Share, Basic and Diluted
Three Months Ended March 31,
Amounts in Millions, Except Per Share Data20222021
Net Earnings Attributable to BMS Used for Basic and Diluted EPS Calculation$1,278 $2,021 
Weighted-Average Common Shares Outstanding – Basic2,146 2,236 
Incremental Shares Attributable to Share-Based Compensation Plans18 29 
Weighted-Average Common Shares Outstanding – Diluted2,164 2,265 
Earnings per Common Share
Basic$0.60 $0.90 
Diluted0.59 0.89 
v3.22.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)
3 Months Ended
Mar. 31, 2022
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
March 31, 2022December 31, 2021
Dollars in MillionsLevel 1Level 2Level 3Level 1Level 2Level 3
Cash and cash equivalents - money market and other securities$— $9,467 $— $— $12,225 $— 
Marketable debt securities:
Certificates of deposit— 2,013 — — 2,264 — 
Commercial paper— 325 — — 320 — 
Corporate debt securities— 261 — — 403 — 
Derivative assets— 288 10 — 206 12 
Equity investments1,410 44 — 1,910 109 — 
Derivative liabilities— 58 — — 25 — 
Contingent consideration liability:
Contingent value rights— — — — 
Other acquisition related contingent consideration— — 34 — — 35 
Marketable Securities
The following table summarizes marketable debt securities:
March 31, 2022December 31, 2021
Dollars in MillionsAmortized CostGross UnrealizedAmortized CostGross Unrealized
GainsLossesFair ValueGainsLossesFair Value
Certificates of deposit$2,013 $— $— $2,013 $2,264 $— $— $2,264 
Commercial paper325 — — 325 320 — — 320 
Corporate debt securities260 — 261 401 — 403 
Total marketable debt securities(a)
$2,598 $$— $2,599 $2,985 $$— $2,987 
(a)    All marketable debt securities mature within one year as of March 31, 2022 and December 31, 2021.
Schedule of Equity Investments
The following summarizes the carrying amount of equity investments:
Dollars in MillionsMarch 31,
2022
December 31,
2021
Equity investments with readily determinable fair values$1,454 $2,019 
Equity investments without readily determinable fair values330 283 
Equity method investments629 666 
Total equity investments$2,413 $2,968 
Debt Securities, Trading, and Equity Securities, FV-NI
The following summarizes the activity related to equity investments. Changes in fair value of equity investments are included in Other (income)/expense, net.
Three Months Ended March 31,
Dollars in Millions20222021
Equity investments with readily determined fair values(a)
Net loss/(gain) recognized$598 $(196)
Net loss recognized on investments sold— 
Net unrealized loss/(gain) recognized on investments still held598 (199)
Equity investments without readily determinable fair values
Upward adjustments(6)(269)
Impairments and downward adjustments
Cumulative upward adjustments(109)
Cumulative impairments and downward adjustments52 
Equity in net (income)/loss of affiliates50 (137)
(a)    Certain prior year amounts have been reclassified to conform to the current year's presentation.
Schedule of Derivatives and Fair Value
The following table summarizes the fair value of outstanding derivatives:
 March 31, 2022December 31, 2021
Asset(a)
Liability(b)
Asset(a)
Liability(b)
Dollars in MillionsNotionalFair ValueNotionalFair ValueNotionalFair ValueNotionalFair Value
Derivatives designated as hedging instruments:
Interest rate swap contracts$— $— $255 $(3)$255 $10 $— $— 
Cross-currency interest rate swap contracts450 37 150 (1)600 26 — — 
Foreign currency forward contracts5,409 230 2,492 (44)3,587 161 1,814 (20)
Derivatives not designated as hedging instruments:
Foreign currency forward contracts744 21 629 (10)883 568 (5)
Other— 10 — — — 12 — — 
(a)    Included in Other current assets and Other non-current assets.
(b)    Included in Other current liabilities and Other non-current liabilities.
Derivative Instruments, Gain (Loss)
The following table summarizes the financial statement classification and amount of (gain)/loss recognized on hedging instruments:
Three Months Ended March 31, 2022Three Months Ended March 31, 2021
Dollars in MillionsCost of products soldOther (income)/expense, netCost of products soldOther (income)/expense, net
Interest rate swap contracts$— $(11)$— $(8)
Cross-currency interest rate swap contracts— (4)— (3)
Foreign currency forward contracts(82)(57)67 (32)

The following table summarizes the effect of derivative and non-derivative instruments designated as hedging instruments in Other Comprehensive Income:
Three Months Ended March 31,
Dollars in Millions20222021
Derivatives qualifying as cash flow hedges
Foreign currency forward contracts gain/(loss):
Recognized in Other Comprehensive Income(a)
$120 $259 
Reclassified to Cost of products sold(82)36 
Forward starting interest rate swap contract loss:
Reclassified to Other (income)/expense, net(3)— 
Derivatives qualifying as net investment hedges
Cross-currency interest rate swap contracts gain:
Recognized in Other Comprehensive Income13 26 
Non-derivatives qualifying as net investment hedges
Non-U.S. dollar borrowings gain:
Recognized in Other Comprehensive Income15 41 
(a)    The majority is expected to be reclassified into earnings in the next 18 months.
Schedule of Short-term Debt
Short-term debt obligations include:
Dollars in MillionsMarch 31,
2022
December 31,
2021
Non-U.S. short-term borrowings$130 $105 
Current portion of long-term debt7,297 4,764 
Other95 79 
Total$7,522 $4,948 
Schedule of Fair Value and Other Adjustments to Long Term Debt
Long-term debt and the current portion of long-term debt include:
Dollars in MillionsMarch 31,
2022
December 31,
2021
Principal Value$43,925 $43,095 
Adjustments to Principal Value:
Fair value of interest rate swap contracts(4)10 
Unamortized basis adjustment from swap terminations113 119 
Unamortized bond discounts and issuance costs(303)(263)
Unamortized purchase price adjustments of Celgene debt1,016 1,408 
Total$44,747 $44,369 
Current portion of long-term debt$7,297 $4,764 
Long-term debt37,450 39,605 
Total$44,747 $44,369 
v3.22.1
RECEIVABLES (Tables)
3 Months Ended
Mar. 31, 2022
Accounts Receivable, after Allowance for Credit Loss [Abstract]  
Schedule Of Receivables
Dollars in MillionsMarch 31,
2022
December 31,
2021
Trade receivables$7,746 $8,723 
Less charge-backs and cash discounts(561)(723)
Less allowance for expected credit loss(29)(21)
Net trade receivables7,156 7,979 
Alliance, Royalties, VAT and other1,355 1,390 
Receivables$8,511 $9,369 
v3.22.1
INVENTORIES (Tables)
3 Months Ended
Mar. 31, 2022
Inventory, Net [Abstract]  
Inventories
Dollars in MillionsMarch 31,
2022
December 31,
2021
Finished goods$449 $543 
Work in process2,052 2,111 
Raw and packaging materials446 350 
Total inventories$2,947 $3,004 
Inventories$2,104 $2,095 
Other non-current assets843 909 
v3.22.1
PROPERTY, PLANT AND EQUIPMENT (Tables)
3 Months Ended
Mar. 31, 2022
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment
Dollars in MillionsMarch 31,
2022
December 31,
2021
Land$168 $169 
Buildings5,941 5,897 
Machinery, equipment and fixtures3,306 3,252 
Construction in progress800 764 
Gross property, plant and equipment10,215 10,082 
Less accumulated depreciation(4,168)(4,033)
Property, plant and equipment$6,047 $6,049 
v3.22.1
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
3 Months Ended
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule Of Intangible Assets By Major Class
Dollars in MillionsEstimated Useful LivesMarch 31,
2022
December 31,
2021
Goodwill$20,500 $20,502 
Other intangible assets:
Licenses
5 – 15 years
307 307 
Acquired marketed product rights
3 – 15 years
60,477 60,454 
Capitalized software
3 – 10 years
1,544 1,499 
IPRD3,710 3,750 
Gross other intangible assets66,038 66,010 
Less accumulated amortization(25,935)(23,483)
Other intangible assets$40,103 $42,527 
v3.22.1
Supplemental Financial Information (Tables)
3 Months Ended
Mar. 31, 2022
Supplemental Financial Information [Abstract]  
Schedule of Other Current Assets
Dollars in MillionsMarch 31,
2022
December 31, 2021
Income taxes$2,182 $2,786 
Research and development604 514 
Contract assets410 361 
Equity investments228 255 
Restricted cash(a)
155 140 
Other959 776 
Other current assets$4,538 $4,832 
Schedule of Other Assets, Noncurrent
Dollars in MillionsMarch 31,
2022
December 31, 2021
Equity investments$2,185 $2,713 
Inventories843 909 
Operating leases894 919 
Pension and postretirement321 317 
Research and development319 248 
Restricted cash(a)
55 197 
Other228 232 
Other non-current assets$4,845 $5,535 
(a)    Restricted cash consists of funds restricted for annual Company contributions to the defined contribution plan in the U.S. and escrow for litigation settlements. Cash is restricted when withdrawal or general use is contractually or legally restricted.
Schedule of Other Current Liabilities
Dollars in MillionsMarch 31,
2022
December 31, 2021
Rebates and discounts$5,455 $6,399 
Income taxes930 754 
Employee compensation and benefits662 1,375 
Research and development1,321 1,373 
Dividends1,151 1,186 
Interest356 378 
Royalties354 410 
Operating leases171 169 
Other1,955 1,927 
Other current liabilities$12,355 $13,971 
Other Noncurrent Liabilities
Dollars in MillionsMarch 31,
2022
December 31, 2021
Income taxes payable$4,889 $4,835 
Pension and postretirement625 654 
Operating leases852 874 
Deferred income319 326 
Deferred compensation409 427 
Other215 218 
Other non-current liabilities$7,309 $7,334 
v3.22.1
EQUITY (Tables)
3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Schedule of Stock by Class
The following table summarizes changes in equity for the three months ended March 31, 2022:
Common StockCapital in Excess of Par Value of StockAccumulated Other Comprehensive LossRetained EarningsTreasury StockNoncontrolling Interest
Dollars and Shares in MillionsSharesPar ValueSharesCost
Balance at December 31, 20212,923 $292 $44,361 $(1,268)$23,820 747 $(31,259)$60 
Net Earnings— — — — 1,278 — — 
Other Comprehensive Income— — — 39 — — — — 
Cash dividends declared(a)
— — — — (1,150)— — — 
Share repurchase program— — (750)— — 65 (4,250)— 
Stock compensation— — 145 — — (18)322 — 
Balance at March 31, 20222,923 $292 $43,756 $(1,229)$23,948 794 $(35,187)$65 
(a)    Cash dividends declared per common share were $0.54 for the three months ended March 31, 2022.

The following table summarizes changes in equity for the three months ended March 31, 2021:
Common StockCapital in Excess of Par Value of StockAccumulated Other Comprehensive LossRetained EarningsTreasury StockNoncontrolling Interest
Dollars and Shares in MillionsSharesPar ValueSharesCost
Balance at December 31, 20202,923 $292 $44,325 $(1,839)$21,281 679 $(26,237)$60 
Net Earnings— — — — 2,021 — — 
Other Comprehensive Income— — — 295 — — — — 
Cash dividends declared(a)
— — — — (1,098)— — — 
Share repurchase program— — — — — 28 (1,768)— 
Stock compensation— — (473)— — (15)806 — 
Balance at March 31, 20212,923 $292 $43,852 $(1,544)$22,204 692 $(27,199)$68 
(a)    Cash dividends declared per common share were $0.49 for the three months ended March 31, 2021.
Schedule of Comprehensive Income Loss
The components of Other Comprehensive Income were as follows:
20222021
Dollars in MillionsPretaxTaxAfter TaxPretaxTaxAfter Tax
Three Months Ended March 31,
Derivatives qualifying as cash flow hedges:
Unrealized gains/(losses)$120 $(16)$104 $259 $(11)$248 
Reclassified to net earnings(a)
(85)12 (73)36 (4)32 
Derivatives qualifying as cash flow hedges35 (4)31 295 (15)280 
Pension and postretirement benefits:
Actuarial losses20 (4)16 21 (5)16 
Amortization(b)
(2)(3)
Settlements(b)
— — 
Pension and postretirement benefits27 (6)21 31 (8)23 
Marketable debt securities:
Unrealized (losses)/gains(2)(1)(3)(2)
Foreign currency translation(6)(6)(12)(15)(6)
Other Comprehensive Income$54 $(15)$39 $332 $(37)$295 
(a)Included in Cost of products sold.
(b)Included in Other (income)/expense, net.
Schedule of Accumulated Other Comprehensive Income Loss
The accumulated balances related to each component of Other Comprehensive Income, net of taxes, were as follows:
Dollars in MillionsMarch 31,
2022
December 31,
2021
Derivatives qualifying as cash flow hedges$209 $178 
Pension and postretirement benefits(747)(768)
Marketable debt securities
Foreign currency translation(692)(680)
Accumulated other comprehensive loss$(1,229)$(1,268)
v3.22.1
EMPLOYEE STOCK BENEFIT PLANS (Tables)
3 Months Ended
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]  
Share-based Payment Arrangement, Cost by Plan
Stock-based compensation expense was as follows:
 Three Months Ended March 31,
Dollars in Millions20222021
Cost of products sold$$15 
Marketing, selling and administrative48 60 
Research and development51 70 
Other (income)/expense, net— 
Total stock-based compensation expense$107 $151 
Income tax benefit(a)
$22 $31 
(a)    Income tax benefit excludes excess tax benefits from share-based compensation awards that were vested or exercised of $40 million and $17 million for the three months ended March 31, 2022 and 2021, respectively.
Schedule Of Share Based Compensation Additional Information
The number of units granted and the weighted-average fair value on the grant date for the three months ended March 31, 2022 were as follows:
Units in MillionsUnitsWeighted-Average Fair Value
Restricted stock units7.2 $63.13 
Market share units1.0 60.72 
Performance share units1.4 66.73 
Share-based Payment Arrangement, Nonvested Award, Cost
Dollars in MillionsStock OptionsRestricted Stock UnitsMarket Share UnitsPerformance Share Units
Unrecognized compensation cost$$1,003 $90 $157 
Expected weighted-average period in years of compensation cost to be recognized0.43.13.42.2
v3.22.1
Revenue - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Disaggregation of Revenue [Line Items]    
Total Revenues $ 11,648 $ 11,073
Net product sales    
Disaggregation of Revenue [Line Items]    
Total Revenues 11,308 10,798
Other revenues    
Disaggregation of Revenue [Line Items]    
Total Revenues 152 133
Alliance revenues    
Disaggregation of Revenue [Line Items]    
Total Revenues 3,427 3,024
Alliance revenues | Net product sales    
Disaggregation of Revenue [Line Items]    
Total Revenues 3,239 2,882
Alliance revenues | Alliance revenues    
Disaggregation of Revenue [Line Items]    
Total Revenues $ 188 $ 142
v3.22.1
Revenue - Reconciliation of Gross Product Sales to Net Product Sales (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Gross to Net Adjustments [Line Items]    
Total Revenues $ 11,648 $ 11,073
Gross to Net Adjustments (5,342) (4,761)
Adjustments for provisions for product sales made in prior periods 74 217
Gross product sales    
Gross to Net Adjustments [Line Items]    
Total Revenues 16,650 15,559
Net product sales    
Gross to Net Adjustments [Line Items]    
Total Revenues 11,308 10,798
Charge-backs and cash discounts    
Gross to Net Adjustments [Line Items]    
Gross to Net Adjustments (1,763) (1,586)
Medicaid and Medicare rebates    
Gross to Net Adjustments [Line Items]    
Gross to Net Adjustments (2,084) (1,718)
Other rebates, returns, discounts and adjustments    
Gross to Net Adjustments [Line Items]    
Gross to Net Adjustments $ (1,495) $ (1,457)
v3.22.1
Revenue - Disaggregation of Revenue by Product and Region (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenue from External Customer [Line Items]    
Total Revenues $ 11,648 $ 11,073
Performance obligation satisfied in previous period 147 284
United States    
Revenue from External Customer [Line Items]    
Total Revenues 7,694 7,010
Europe    
Revenue from External Customer [Line Items]    
Total Revenues 2,413 2,553
Rest of the World    
Revenue from External Customer [Line Items]    
Total Revenues 1,314 1,346
Other Region    
Revenue from External Customer [Line Items]    
Total Revenues 227 164
Eliquis    
Revenue from External Customer [Line Items]    
Total Revenues 3,211 2,886
Opdivo    
Revenue from External Customer [Line Items]    
Total Revenues 1,923 1,720
Pomalyst/Imnovid    
Revenue from External Customer [Line Items]    
Total Revenues 826 773
Orencia    
Revenue from External Customer [Line Items]    
Total Revenues 792 758
Sprycel    
Revenue from External Customer [Line Items]    
Total Revenues 483 470
Yervoy    
Revenue from External Customer [Line Items]    
Total Revenues 515 456
Empliciti    
Revenue from External Customer [Line Items]    
Total Revenues 75 85
Mature and other products    
Revenue from External Customer [Line Items]    
Total Revenues 462 506
Reblozyl    
Revenue from External Customer [Line Items]    
Total Revenues 156 112
Abecma    
Revenue from External Customer [Line Items]    
Total Revenues 67 0
Zeposia    
Revenue from External Customer [Line Items]    
Total Revenues 36 18
Breyanzi    
Revenue from External Customer [Line Items]    
Total Revenues 44 0
Inrebic    
Revenue from External Customer [Line Items]    
Total Revenues 18 16
Onureg    
Revenue from External Customer [Line Items]    
Total Revenues 23 15
Opdualag    
Revenue from External Customer [Line Items]    
Total Revenues 6 0
Revlimid    
Revenue from External Customer [Line Items]    
Total Revenues 2,797 2,944
Abraxane    
Revenue from External Customer [Line Items]    
Total Revenues $ 214 $ 314
v3.22.1
ALLIANCES (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Alliance Statement [Line Items]      
Total Revenues $ 11,648 $ 11,073  
Cost of products sold [1] 2,471 2,841  
Research and development 2,260 2,219  
Other (income)/expense, net 649 (702)  
Receivables – from alliance partners 8,511   $ 9,369
Accounts payable – to alliance partners 2,944   2,949
Alliance revenues      
Alliance Statement [Line Items]      
Total Revenues 3,427 3,024  
Cost of products sold 1,556 1,397  
Marketing, selling and administrative (54) (49)  
Research and development 22 7  
Other (income)/expense, net (12) (5)  
Receivables – from alliance partners 304   320
Accounts payable – to alliance partners 1,504   1,229
Deferred income from alliance 326   $ 330
Net product sales      
Alliance Statement [Line Items]      
Total Revenues 11,308 10,798  
Net product sales | Alliance revenues      
Alliance Statement [Line Items]      
Total Revenues 3,239 2,882  
Alliance revenues | Alliance revenues      
Alliance Statement [Line Items]      
Total Revenues $ 188 $ 142  
[1] Excludes amortization of acquired intangible assets
v3.22.1
DIVESTITURES, LICENSING AND OTHER ACQUISITIONS - Divestitures (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Business Acquisition [Line Items]    
Net proceeds $ 397 $ 180
Divestiture (Gains)/Losses (211) 0
Royalty Income (171) (135)
Diabetes Business    
Business Acquisition [Line Items]    
Net proceeds 172 164
Divestiture (Gains)/Losses 0 0
Royalty Income (170) (134)
Mature Products and Other    
Business Acquisition [Line Items]    
Net proceeds 225 16
Divestiture (Gains)/Losses (211) 0
Royalty Income (1) $ (1)
Mature Products and Other | Cheplapharm    
Business Acquisition [Line Items]    
Net proceeds $ 221  
v3.22.1
DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Licensing and Other Arrangements (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Royalty income, nonoperating $ (171) $ (135)
Contingent milestone income (41) 0
Amortization of deferred income (12) (15)
Licensing and Other Arrangements Income (306) (232)
Immatics    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Upfront payments 150  
Dragonfly    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Upfront payments 175  
Keytruda Royalties    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Royalty income, nonoperating (221) (192)
Tecentriq royalties    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Royalty income, nonoperating (25) (22)
Other Royalties    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Royalty income, nonoperating $ (7) $ (3)
v3.22.1
DIVENSTITURES, LICENSING AND OTHER ARRANGEMENTS - Additional Information (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended
Apr. 30, 2022
Mar. 31, 2022
Mar. 31, 2021
Licensing Arrangements [Line Items]      
Proceeds from divestiture of businesses, net of cash divested   $ 397 $ 180
Divestiture gains   211 0
Subsequent Event      
Licensing Arrangements [Line Items]      
Payment to extinguish future royalty obligation $ 295    
Immatics      
Licensing Arrangements [Line Items]      
Upfront payments   150  
Contingent and regulatory milestone payments   770  
Mature Products and Other      
Licensing Arrangements [Line Items]      
Proceeds from divestiture of businesses, net of cash divested   225 16
Divestiture gains   $ 211 $ 0
v3.22.1
OTHER (INCOME)/EXPENSE, NET - Schedule Of Other Income Expense (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Other Nonoperating Income (Expense) [Abstract]    
Interest expense $ 326 $ 353
Royalties and licensing income (477) (367)
Equity investment losses/(gains) 644 (601)
Integration expenses 105 141
Contingent consideration 1 (510)
Loss on debt redemption 275 281
Provision for restructuring 23 45
Litigation and other settlements (37) (8)
Transition and other service fees (1) (15)
Investment income (10) (9)
Divestiture gains (211) 0
Other 11 (12)
Other (income)/expense, net $ 649 $ (702)
v3.22.1
RESTRUCTURING - Additional Information (Details)
$ in Millions
3 Months Ended
Mar. 31, 2022
USD ($)
employee
Dec. 31, 2019
USD ($)
Cost of products sold    
Restructuring Cost and Reserve [Line Items]    
Expected synergies, percentage 0.05  
Marketing, selling and administrative    
Restructuring Cost and Reserve [Line Items]    
Expected synergies, percentage 0.65  
Research and development    
Restructuring Cost and Reserve [Line Items]    
Expected synergies, percentage 0.30  
Celgene Acquisition Plan    
Restructuring Cost and Reserve [Line Items]    
Expected cost savings and avoidance   $ 3,000
Expected restructuring and related charges $ 3,300  
Restructuring and related charges incurred to date 2,700  
Cash outlays $ 3,000  
Workforce reduction of manufacturing, selling, administrative, and research and development personnel | employee 60  
MyoKardia Acquisition Plan    
Restructuring Cost and Reserve [Line Items]    
Expected restructuring and related charges $ 150  
Restructuring and related charges incurred to date $ 120  
v3.22.1
RESTRUCTURING - Schedule of Restructuring and Related Costs (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Restructuring Cost and Reserve [Line Items]    
Total charges $ 130 $ 210
Employee termination costs 22 44
Other termination costs 1 1
Provision for restructuring 23 45
Integration expenses 105 141
Accelerated depreciation 2 0
Asset impairments 0 24
Cost of products sold    
Restructuring Cost and Reserve [Line Items]    
Total charges 0 24
Marketing, selling and administrative    
Restructuring Cost and Reserve [Line Items]    
Total charges 2 0
Other (income)/expense, net    
Restructuring Cost and Reserve [Line Items]    
Total charges 128 186
Celgene Acquisition Plan    
Restructuring Cost and Reserve [Line Items]    
Total charges 127 173
MyoKardia Acquisition Plan    
Restructuring Cost and Reserve [Line Items]    
Total charges $ 3 $ 37
v3.22.1
RESTRUCTURING - Schedule of Restructuring Reserve by Type of Cost (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Restructuring reserve, beginning of period $ 101 $ 148
Restructuring charges 23 39
Foreign currency translation and other (1) (2)
Payments (21) (59)
Restructuring reserve, end of period 102 126
Change in estimates 9 1
Provision for restructuring $ 23 45
Celgene Acquisition Plan | Accelerated Stock Based Compensation    
Provision for restructuring   $ 6
v3.22.1
INCOME TAXES - Schedule of Provision for Income Taxes (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Tax Disclosure [Abstract]    
Earnings Before Income Taxes $ 1,687 $ 2,530
Provision for Income Taxes $ 404 $ 501
Effective Tax Rate 23.90% 19.80%
v3.22.1
INCOME TAXES - Additional Information (Details)
$ in Millions
Mar. 31, 2022
USD ($)
Minimum  
Reasonably possible decrease in unrecognized tax benefits $ 450
Maximum  
Reasonably possible decrease in unrecognized tax benefits $ 500
v3.22.1
EARNINGS PER SHARE (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Earnings Per Share [Abstract]    
Net Earnings Attributable to BMS Used for Basic and Diluted EPS Calculation $ 1,278 $ 2,021
Weighted-average common shares outstanding - basic (in shares) 2,146 2,236
Incremental shares attributable to share-based compensation plans (in shares) 18 29
Weighted-average common shares outstanding - diluted (in shares) 2,164 2,265
Earnings per common share attributable to BMS, basic (in usd per share) $ 0.60 $ 0.90
Earnings per common share attributable to BMS, diluted (in usd per share) $ 0.59 $ 0.89
v3.22.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable debt securities $ 2,599 $ 2,987
Equity investments 1,454 2,019
Certificates of deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable debt securities 2,013 2,264
Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable debt securities 325 320
Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable debt securities 261 403
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents - money market and other securities 0 0
Derivative assets 0 0
Derivative liabilities 0 0
Contingent consideration liability 0 0
Level 1 | Other Assets    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity investments 1,410 1,910
Level 1 | Contingent value rights    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration liability 6 8
Level 1 | Certificates of deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable debt securities 0 0
Level 1 | Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable debt securities 0 0
Level 1 | Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable debt securities 0 0
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents - money market and other securities 9,467 12,225
Derivative assets 288 206
Derivative liabilities 58 25
Contingent consideration liability 0 0
Level 2 | Other Assets    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity investments 44 109
Level 2 | Contingent value rights    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration liability 0 0
Level 2 | Certificates of deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable debt securities 2,013 2,264
Level 2 | Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable debt securities 325 320
Level 2 | Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable debt securities 261 403
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents - money market and other securities 0 0
Derivative assets 10 12
Derivative liabilities 0 0
Contingent consideration liability 34 35
Level 3 | Other Assets    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity investments 0 0
Level 3 | Contingent value rights    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration liability 0 0
Level 3 | Certificates of deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable debt securities 0 0
Level 3 | Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable debt securities 0 0
Level 3 | Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable debt securities $ 0 $ 0
v3.22.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Available-for-sale Securities (Details) - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Cost $ 2,598 $ 2,985
Gross unrealized gains 1 2
Gross unrealized losses 0 0
Marketable debt securities, fair value 2,599 2,987
Certificates of deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Cost 2,013 2,264
Gross unrealized gains 0 0
Gross unrealized losses 0 0
Marketable debt securities, fair value 2,013 2,264
Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Cost 325 320
Gross unrealized gains 0 0
Gross unrealized losses 0 0
Marketable debt securities, fair value 325 320
Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Cost 260 401
Gross unrealized gains 1 2
Gross unrealized losses 0 0
Marketable debt securities, fair value $ 261 $ 403
v3.22.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Summary of Equity Investments Carrying Amount (Details) - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Fair Value Disclosures [Abstract]    
Equity investments with readily determinable fair values $ 1,454 $ 2,019
Equity investments without readily determinable fair values 330 283
Equity method investments 629 666
Total equity investments $ 2,413 $ 2,968
v3.22.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS -Schedule of Equity Investments (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Equity investments with readily determined fair values    
Net loss/(gain) recognized $ 598 $ (196)
Net loss recognized on investments sold 0 3
Net unrealized loss/(gain) recognized on investments still held 598 (199)
Equity investments without readily determinable fair values    
Upward adjustments (6) (269)
Impairments and downward adjustments 2 1
Cumulative upward adjustments (109)
Cumulative impairments and downward adjustments 52
Equity in net (income)/loss of affiliates $ 50 $ (137)
v3.22.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Additional Information (Details)
€ in Millions, $ in Millions, ¥ in Billions
1 Months Ended 3 Months Ended
Apr. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Mar. 31, 2022
EUR (€)
Mar. 31, 2022
JPY (¥)
Feb. 28, 2022
USD ($)
Dec. 31, 2021
USD ($)
creditFacility
Derivative [Line Items]              
Principal Value   $ 43,925         $ 43,095
Variable rate debt, lower range of basis point spread   4.60%   4.60% 4.60%    
Long-term debt, fair value   $ 45,800         $ 49,100
Deferred loan issuance costs   5,926 $ 0        
Extinguishment of debt   5,200 3,500        
Payment for debt extinguishment   5,800 4,000        
Loss on debt redemption   275 281        
Interest payments   377 435        
Number of revolving credit facilities | creditFacility             4
Line of credit facility, maximum borrowing capacity             $ 6,000
Subsequent Event              
Derivative [Line Items]              
Extinguishment of debt $ 849            
Payment for debt extinguishment $ 880            
$2 Billion Maximum Borrowing Capacity              
Derivative [Line Items]              
Line of credit facility, maximum borrowing capacity   2,000         2,000
$1 Billion Maximum Borrowing Capacity              
Derivative [Line Items]              
Line of credit facility, maximum borrowing capacity   1,000         1,000
$1.5 Billion Maximum Borrowing Capacity              
Derivative [Line Items]              
Line of credit facility, maximum borrowing capacity   $ 1,500         $ 1,500
Long-term debt, term (in years)   5 years   5 years 5 years    
$5 Billion Maximum Borrowing Capacity              
Derivative [Line Items]              
Line of credit facility, maximum borrowing capacity   $ 5,000          
Long-term debt, term (in years)   5 years   5 years 5 years    
Renewal period   1 year   1 year 1 year    
$6.0 Billion Fixed Rate Unsecured Senior Notes              
Derivative [Line Items]              
Principal Value   $ 6,000          
Senior Unsecured Notes Due 2032 | Senior Notes              
Derivative [Line Items]              
Principal Value   $ 1,750          
Interest rates   2.95%   2.95% 2.95%    
Senior Unsecured Notes Due 2042 | Senior Notes              
Derivative [Line Items]              
Principal Value   $ 1,250          
Interest rates   3.55%   3.55% 3.55%    
Senior Unsecured Notes Due 2052 | Senior Notes              
Derivative [Line Items]              
Principal Value   $ 2,000          
Interest rates   3.70%   3.70% 3.70%    
Senior Unsecured Notes Due 2062 | Senior Notes              
Derivative [Line Items]              
Principal Value   $ 1,000          
Interest rates   3.90%   3.90% 3.90%    
2.875% Senior Notes due 2021              
Derivative [Line Items]              
Principal Value     $ 500        
London Interbank Offered Rate (LIBOR)              
Derivative [Line Items]              
LIBOR   0.45%   0.45% 0.45%    
Designated as Hedging Instrument              
Derivative [Line Items]              
Principal Value   $ 1,100   € 950      
Designated as Hedging Instrument | Treasury lock contracts              
Derivative [Line Items]              
Derivative, notional amount   2,300       $ 3,000  
Euro Member Countries, Euro | Designated as Hedging Instrument | Foreign currency forward contracts              
Derivative [Line Items]              
Derivative, notional amount | €       € 5,300      
Japan, Yen | Designated as Hedging Instrument | Foreign currency forward contracts              
Derivative [Line Items]              
Derivative, notional amount | ¥         ¥ 1.3    
Japan, Yen | Designated as Hedging Instrument | Cross-currency interest rate swap contracts              
Derivative [Line Items]              
Derivative, notional amount   $ 600          
v3.22.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Derivatives and Fair Value (Details) - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Interest rate swap contracts    
Derivatives, Fair Value [Line Items]    
Derivative liabilities $ (4) $ 10
Designated as Hedging Instrument | Interest rate swap contracts    
Derivatives, Fair Value [Line Items]    
Derivative assets 0 10
Derivative liabilities (3) 0
Designated as Hedging Instrument | Interest rate swap contracts | Assets    
Derivatives, Fair Value [Line Items]    
Derivative, notional amount 0 255
Designated as Hedging Instrument | Interest rate swap contracts | Liability    
Derivatives, Fair Value [Line Items]    
Derivative, notional amount 255 0
Designated as Hedging Instrument | Cross-currency interest rate swap contracts    
Derivatives, Fair Value [Line Items]    
Derivative assets 37 26
Derivative liabilities (1) 0
Designated as Hedging Instrument | Cross-currency interest rate swap contracts | Assets    
Derivatives, Fair Value [Line Items]    
Derivative, notional amount 450 600
Designated as Hedging Instrument | Cross-currency interest rate swap contracts | Liability    
Derivatives, Fair Value [Line Items]    
Derivative, notional amount 150 0
Designated as Hedging Instrument | Foreign currency forward contracts    
Derivatives, Fair Value [Line Items]    
Derivative assets 230 161
Derivative liabilities (44) (20)
Designated as Hedging Instrument | Foreign currency forward contracts | Assets    
Derivatives, Fair Value [Line Items]    
Derivative, notional amount 5,409 3,587
Designated as Hedging Instrument | Foreign currency forward contracts | Liability    
Derivatives, Fair Value [Line Items]    
Derivative, notional amount 2,492 1,814
Not Designated as Hedging Instrument | Foreign currency forward contracts    
Derivatives, Fair Value [Line Items]    
Derivative assets 21 9
Derivative liabilities (10) (5)
Not Designated as Hedging Instrument | Foreign currency forward contracts | Assets    
Derivatives, Fair Value [Line Items]    
Derivative, notional amount 744 883
Not Designated as Hedging Instrument | Foreign currency forward contracts | Liability    
Derivatives, Fair Value [Line Items]    
Derivative, notional amount 629 568
Not Designated as Hedging Instrument | Other    
Derivatives, Fair Value [Line Items]    
Derivative assets 10 12
Derivative liabilities 0 0
Not Designated as Hedging Instrument | Other | Assets    
Derivatives, Fair Value [Line Items]    
Derivative, notional amount 0 0
Not Designated as Hedging Instrument | Other | Liability    
Derivatives, Fair Value [Line Items]    
Derivative, notional amount $ 0 $ 0
v3.22.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Derivative Instruments, Gain (Loss) (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Interest rate swap contracts | Cost of products sold    
Derivative Instruments, Gain (Loss) [Line Items]    
Gain (loss) on derivative, net $ 0 $ 0
Interest rate swap contracts | Other (income)/expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Gain (loss) on derivative, net (11) (8)
Cross-currency interest rate swap contracts | Cost of products sold    
Derivative Instruments, Gain (Loss) [Line Items]    
Gain (loss) on derivative, net 0 0
Cross-currency interest rate swap contracts | Other (income)/expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Gain (loss) on derivative, net (4) (3)
Foreign currency forward contracts | Cost of products sold    
Derivative Instruments, Gain (Loss) [Line Items]    
Gain (loss) on derivative, net (82) 67
Foreign currency forward contracts | Other (income)/expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Gain (loss) on derivative, net $ (57) $ (32)
v3.22.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Gain/(Loss) on Hedging Activity (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Foreign currency forward contracts gain/(loss):    
Recognized in other comprehensive income $ 120 $ 259
Reclassified to net earnings, pretax (85) 36
Non-U.S. dollar borrowings gain:    
Recognized in Other Comprehensive Income (6) 9
Designated as Hedging Instrument    
Non-U.S. dollar borrowings gain:    
Recognized in Other Comprehensive Income 15 41
Foreign currency forward contracts    
Foreign currency forward contracts gain/(loss):    
Recognized in other comprehensive income 120 259
Foreign currency forward contracts | Cost of products sold    
Foreign currency forward contracts gain/(loss):    
Reclassified to net earnings, pretax (82) 36
Interest rate swap contracts | Reclassified to Other (income)/expense, net    
Foreign currency forward contracts gain/(loss):    
Reclassified to net earnings, pretax (3) 0
Cross-currency interest rate swap contracts    
Cross-currency interest rate swap contracts gain:    
Recognized in Other Comprehensive Income $ 13 $ 26
v3.22.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Short-term Debt (Details) - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Fair Value Disclosures [Abstract]    
Non-U.S. short-term borrowings $ 130 $ 105
Current portion of long-term debt 7,297 4,764
Other 95 79
Short-term debt, total $ 7,522 $ 4,948
v3.22.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Long-term and Current Debt Instruments (Details) - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Debt Instrument [Line Items]    
Principal Value $ 43,925 $ 43,095
Unamortized basis adjustment from swap terminations 113 119
Unamortized bond discounts and issuance costs (303) (263)
Unamortized purchase price adjustments of Celgene debt 1,016 1,408
Total long-term debt 44,747 44,369
Current portion of long-term debt 7,297 4,764
Long-term debt 37,450 39,605
Interest rate swap contracts    
Debt Instrument [Line Items]    
Fair value of interest rate swap contracts $ (4) $ 10
v3.22.1
RECEIVABLES - Schedule of Receivables (Details) - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Accounts Receivable, after Allowance for Credit Loss [Abstract]    
Trade receivables $ 7,746 $ 8,723
Less charge-backs and cash discounts (561) (723)
Less allowance for expected credit loss (29) (21)
Net trade receivables 7,156 7,979
Alliance, Royalties, VAT and other 1,355 1,390
Receivables $ 8,511 $ 9,369
v3.22.1
RECEIVABLES (Details)
$ in Millions
3 Months Ended
Mar. 31, 2022
USD ($)
customers
Mar. 31, 2021
USD ($)
Dec. 31, 2021
Account Receivables [Line Items]      
Non-U.S. receivables sold on a nonrecourse basis | $ $ 423 $ 318  
Number of largest pharmaceutical wholesalers | customers 3    
Customer Concentration Risk      
Account Receivables [Line Items]      
Percent of aggregate total trade receivables due from three pharmaceutical wholesalers 60.00%   59.00%
v3.22.1
INVENTORIES (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Finished goods $ 449   $ 543
Work in process 2,052   2,111
Raw and packaging materials 446   350
Total inventories 2,947   3,004
Inventories 2,104   2,095
Other non-current assets 843   909
Cost of products sold [1] 2,471 $ 2,841  
Research and development 2,260 $ 2,219  
Fair Value Adjustment to Inventory      
Inventory adjustments 114    
Cost of products sold 32    
Research and development 82    
Inventory Purchase Price Fair Value Adjustment      
Inventories, fair value adjustment $ 368   $ 508
[1] Excludes amortization of acquired intangible assets
v3.22.1
PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Property, Plant and Equipment [Abstract]      
Land $ 168   $ 169
Buildings 5,941   5,897
Machinery, equipment and fixtures 3,306   3,252
Construction in progress 800   764
Gross property, plant and equipment 10,215   10,082
Less accumulated depreciation (4,168)   (4,033)
Property, plant and equipment 6,047   $ 6,049
Depreciation expense $ 145 $ 135  
v3.22.1
GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Intangible Assets By Major Class (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]    
Goodwill $ 20,500 $ 20,502
Gross other intangible assets 66,038 66,010
Less accumulated amortization (25,935) (23,483)
Other intangible assets 40,103 42,527
IPRD    
Finite-Lived Intangible Assets [Line Items]    
IPRD 3,710 3,750
Licenses    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, net 307 307
Acquired marketed product rights    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, net 60,477 60,454
Capitalized software    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, net $ 1,544 $ 1,499
Minimum | Licenses    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible asset, useful life 5 years  
Minimum | Acquired marketed product rights    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible asset, useful life 3 years  
Minimum | Capitalized software    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible asset, useful life 3 years  
Maximum | Licenses    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible asset, useful life 15 years  
Maximum | Acquired marketed product rights    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible asset, useful life 15 years  
Maximum | Capitalized software    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible asset, useful life 10 years  
v3.22.1
GOODWILL AND OTHER INTANGIBLE ASSETS - Additional Information (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Finite-Lived Intangible Assets [Line Items]    
Amortization of intangible assets $ 2,500 $ 2,600
Impairment of other intangible assets $ 40  
Inrebic    
Finite-Lived Intangible Assets [Line Items]    
Impairment of other intangible assets   315
Contingent and regulatory milestone   300
Finite-lived intangible assets, net   $ 385
v3.22.1
SUPPLEMENTAL FINANCIAL INFORMATION - Other Current Assets (Details) - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Supplemental Financial Information [Abstract]    
Income taxes $ 2,182 $ 2,786
Research and development 604 514
Contract assets 410 361
Equity investments 228 255
Restricted cash 155 140
Other 959 776
Other current assets $ 4,538 $ 4,832
v3.22.1
SUPPLEMENTAL FINANCIAL INFORMATION - Other Non-Current Assets (Details) - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Supplemental Financial Information [Abstract]    
Equity investments $ 2,185 $ 2,713
Inventories 843 909
Operating leases 894 919
Pension and postretirement 321 317
Research and development 319 248
Restricted cash 55 197
Other 228 232
Other non-current assets $ 4,845 $ 5,535
v3.22.1
SUPPLEMENTAL FINANCIAL INFORMATION - Other Current Liabilities (Details) - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Supplemental Financial Information [Abstract]    
Rebates and discounts $ 5,455 $ 6,399
Income taxes 930 754
Employee compensation and benefits 662 1,375
Research and development 1,321 1,373
Dividends 1,151 1,186
Interest 356 378
Royalties 354 410
Operating leases 171 169
Other 1,955 1,927
Other current liabilities $ 12,355 $ 13,971
v3.22.1
SUPPLEMENTAL FINANCIAL INFORMATION - Other Non-Current Liabilities (Details) - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Supplemental Financial Information [Abstract]    
Income taxes payable $ 4,889 $ 4,835
Pension and postretirement 625 654
Operating leases 852 874
Deferred income 319 326
Deferred compensation 409 427
Other 215 218
Other non-current liabilities $ 7,309 $ 7,334
v3.22.1
EQUITY - Schedule of Stockholders Equity (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Equity [Line Items]    
Beginning balance $ 35,946  
Net Earnings 1,278 $ 2,021
Other Comprehensive Income 39 $ 295
Ending balance $ 31,580  
Dividends declared (in usd per share) $ 0.54 $ 0.49
Common Stock    
Equity [Line Items]    
Beginning balance (in shares) 2,923 2,923
Beginning balance $ 292 $ 292
Ending balance (in shares) 2,923 2,923
Ending balance $ 292 $ 292
Capital in Excess of Par Value of Stock    
Equity [Line Items]    
Beginning balance 44,361 44,325
Share repurchase program (750)  
Stock compensation 145 (473)
Ending balance 43,756 43,852
Accumulated Other Comprehensive Loss    
Equity [Line Items]    
Beginning balance (1,268) (1,839)
Other Comprehensive Income 39 295
Ending balance (1,229) (1,544)
Retained Earnings    
Equity [Line Items]    
Beginning balance 23,820 21,281
Net Earnings 1,278 2,021
Cash dividends declared (1,150) (1,098)
Ending balance $ 23,948 $ 22,204
Treasury Stock    
Equity [Line Items]    
Beginning balance (in shares) 747 679
Beginning balance $ (31,259) $ (26,237)
Share repurchase program (in shares) 65 28
Share repurchase program $ (4,250) $ (1,768)
Stock compensation $ 322 $ 806
Stock compensation (in shares) (18) (15)
Ending balance (in shares) 794 692
Ending balance $ (35,187) $ (27,199)
Noncontrolling Interest    
Equity [Line Items]    
Beginning balance 60 60
Net earnings, noncontrolling interest 5 8
Ending balance $ 65 $ 68
v3.22.1
EQUITY - Additional Information (Details) - USD ($)
shares in Millions, $ in Billions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Equity [Line Items]      
Stock repurchase program, remaining authorized repurchase amount $ 10.2   $ 15.2
Stock repurchase program (in shares)   28  
Stock repurchased during period   $ 1.8  
2022 ASR      
Equity [Line Items]      
Stock repurchase program (in shares) 65    
Stock repurchase program, authorized amount $ 5.0    
v3.22.1
EQUITY - Schedule of Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Equity [Abstract]    
Unrealized gains/(losses), pretax $ 120 $ 259
Unrealized gains/(losses), tax (16) (11)
Unrealized gains/(losses), after tax 104 248
Reclassified to net earnings, pretax (85) 36
Reclassified to net earnings, tax 12 (4)
Reclassified to net earnings, after tax (73) 32
Derivatives qualifying as cash flow hedges, pretax 35 295
Derivatives qualifying as cash flow hedges, tax (4) (15)
Derivatives qualifying as cash flow hedges, after tax 31 280
Actuarial losses, pretax 20 21
Actuarial losses, tax (4) (5)
Actuarial losses, after tax 16 16
Amortization, pretax 6 9
Amortization, tax (2) (3)
Amortization, after tax 4 6
Settlements, pretax 1 1
Settlements, tax 0 0
Settlements, after tax 1 1
Pension and postretirement benefits, pre-tax 27 31
Pension and postretirement benefits, tax (6) (8)
Pension and postretirement benefits, after tax 21 23
Unrealized (losses)/gains, pretax (2) (3)
Unrealized (losses)/gains, tax 1 1
Marketable debt securities (1) (2)
Foreign currency translation, pretax (6) 9
Foreign currency translation, tax (6) (15)
Foreign currency translation, after tax (12) (6)
Other Comprehensive Income/(Loss), pre-tax 54 332
Other comprehensive income/(loss), Tax (15) (37)
Other Comprehensive Income/(Loss), after tax $ 39 $ 295
v3.22.1
EQUITY - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Equity [Abstract]    
Derivatives qualifying as cash flow hedges $ 209 $ 178
Pension and postretirement benefits (747) (768)
Marketable debt securities 1 2
Foreign currency translation (692) (680)
Accumulated other comprehensive loss $ (1,229) $ (1,268)
v3.22.1
EMPLOYEE STOCK BENEFIT PLANS - Stock Based Compensation Expense (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Share-based Payment Arrangement, Expense $ 107 $ 151
Share-based Payment Arrangement, Expense, Tax Benefit 22 31
Excess tax benefits from share-based compensation awards 40 17
Cost of products sold    
Share-based Payment Arrangement, Expense 8 15
Marketing, selling and administrative    
Share-based Payment Arrangement, Expense 48 60
Research and development    
Share-based Payment Arrangement, Expense 51 70
Other (income)/expense, net    
Share-based Payment Arrangement, Expense $ 0 $ 6
v3.22.1
EMPLOYEE STOCK BENEFIT PLANS - Schedule of Share-based Compensation Additional Information (Details)
shares in Millions
3 Months Ended
Mar. 31, 2022
$ / shares
shares
Restricted stock units  
Number of units granted (in shares) | shares 7.2
Weighted-average fair value (in usd per share) | $ / shares $ 63.13
Market share units  
Number of units granted (in shares) | shares 1.0
Weighted-average fair value (in usd per share) | $ / shares $ 60.72
Performance share units  
Number of units granted (in shares) | shares 1.4
Weighted-average fair value (in usd per share) | $ / shares $ 66.73
v3.22.1
EMPLOYEE STOCK BENEFIT PLANS - Share-based Payment Arrangement, Nonvested Award, Cost (Details)
$ in Millions
3 Months Ended
Mar. 31, 2022
USD ($)
Stock Options  
Unrecognized compensation cost $ 3
Expected weighted-average period in years of compensation cost to be recognized 4 months 24 days
Restricted stock units  
Unrecognized compensation cost $ 1,003
Expected weighted-average period in years of compensation cost to be recognized 3 years 1 month 6 days
Market share units  
Unrecognized compensation cost $ 90
Expected weighted-average period in years of compensation cost to be recognized 3 years 4 months 24 days
Performance share units  
Unrecognized compensation cost $ 157
Expected weighted-average period in years of compensation cost to be recognized 2 years 2 months 12 days
v3.22.1
LEGAL PROCEEDINGS AND CONTINGENCIES (Details)
$ in Millions, $ in Millions
1 Months Ended 3 Months Ended
Feb. 28, 2021
USD ($)
Apr. 30, 2020
USD ($)
Dec. 31, 2019
USD ($)
Sep. 30, 2015
patents
Mar. 31, 2010
AUD ($)
Mar. 31, 2022
USD ($)
lawsuits
numberOfPlaintiffs
Apr. 01, 2022
Jun. 30, 2021
USD ($)
Legal Proceedings And Contingencies [Line Items]                
Running royalty             0.015  
Damages sought | $ $ 834              
Obligation to holders of the contingent value rights | $               $ 6,400
Accrued liabilities for CERCLA matters | $           $ 89    
Bristol-Myers Squibb                
Legal Proceedings And Contingencies [Line Items]                
Damages sought | $ $ 417              
Anti-PD-1 Antibody Litigation                
Legal Proceedings And Contingencies [Line Items]                
Number of patents | patents       6        
CAR T Kite Litigation                
Legal Proceedings And Contingencies [Line Items]                
Payments for royalties | $   $ 1,200 $ 585          
Running royalty   0.276 0.276          
Plavix Australia Intellectual Property | Australia, Dollars                
Legal Proceedings And Contingencies [Line Items]                
Damages paid | $         $ 449      
Plavix Australia Intellectual Property | United States of America, Dollars                
Legal Proceedings And Contingencies [Line Items]                
Damages paid | $           $ 337    
Abilify Product Liability                
Legal Proceedings And Contingencies [Line Items]                
Pending claims | lawsuits           5    
Abilify Product Liability | CANADA                
Legal Proceedings And Contingencies [Line Items]                
Pending claims | lawsuits           11    
Class action claims | lawsuits           4    
Individual injury claims | lawsuits           7    
Pending claims, active | lawsuits           2    
Abilify Product Liability Litigation                
Legal Proceedings And Contingencies [Line Items]                
Pending claims | lawsuits           2,500    
Dismissed cases | lawsuits           2,700    
Number of plaintiffs, dismissed cases | numberOfPlaintiffs           3,900    
Onglyza Product Liability Litigation                
Legal Proceedings And Contingencies [Line Items]                
Number of plaintiffs | numberOfPlaintiffs           252